RESULT_COUNT: 246,PAGE_SIZE: 10000,CURRENT_PAGE: 1,TOTAL_PAGES: 1,API_CALL_CREDITS: 1
TICKER,FIGI_TICKER,FIGI,TITLE,PUBLICATION_DATE,URL,SUMMARY
FGEN,FGEN:UW,BBG0077ZBFS3,Spectrum Shares Surge on Data for Lung Cancer Drug -- Biotech Movers,2017-10-18 13:29:00 +0000,http://finance.yahoo.com/r/26901859-f706-32ba-865f-a66d5f832863/spectrum-shares-surge-data-lung-cancer-drug-biotech-movers?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,"The Henderson, Nev.-based company said interim data from a Phase 2 study showed an objective response rate of 73%."
FGEN,FGEN:UW,BBG0077ZBFS3,FibroGen Announces Acceptance by China FDA of Roxadustat New Drug Application (NDA) for Treatment of Anemia Associated With Dialysis and Non-Dialysis Chronic Kidney Disease (CKD),2017-10-18 11:00:00 +0000,https://finance.yahoo.com/news/fibrogen-announces-acceptance-china-fda-110000327.html?.tsrc=rss,"SAN FRANCISCO, Oct. 18, 2017-- FibroGen, Inc., a science-based biopharmaceutical company, and its subsidiary FibroGen China Medical Technology Development Co., Ltd., today announced that the China Food ..."
FGEN,FGEN:UW,BBG0077ZBFS3,See what the IHS Markit Score report has to say about FibroGen Inc.,2017-10-17 12:04:15 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120415040.html?.tsrc=rss,"Short interest is low for FGEN with fewer than 5% of shares on loan.  The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.  Over the last month, growth of ETFs holding FGEN is favorable, with net inflows of $4.12 billion."
FGEN,FGEN:UW,BBG0077ZBFS3,"ETFs with exposure to FibroGen, Inc. : October 13, 2017",2017-10-13 14:47:46 +0000,http://finance.yahoo.com/r/1e15afad-1e72-380e-a517-a3877a5e8aaa/etfs-with-exposure-to-fibrogen-inc-october-13-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to FibroGen, Inc. Here are 5 ETFs with the largest exposure to FGEN-US. Comparing the performance and risk of FibroGen, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more
<b>(Read more...)</b>"
FGEN,FGEN:UW,BBG0077ZBFS3,Cramer's lightning round: Let Nike walk these losses off,2017-10-10 23:04:00 +0000,https://finance.yahoo.com/video/cramers-lightning-round-let-nike-230400362.html?.tsrc=rss,"Jim Cramer flies through his take on callers' favorite stocks, including the bedraggled Nike."
FGEN,FGEN:UW,BBG0077ZBFS3,3 Under-the-Radar Small Cap Gems,2017-10-02 15:14:00 +0000,http://finance.yahoo.com/r/a93a3dd9-0dec-308d-bf76-2bb0a3d84007/3-undertheradar-small-cap-gems?partner=YahooSA&yptr=yahoo&.tsrc=rss,"The Russell 2000 broke out above three-year resistance last week, a positive sign for its strongest small-cap components."
FGEN,FGEN:UW,BBG0077ZBFS3,"ETFs with exposure to FibroGen, Inc. : October 2, 2017",2017-10-02 14:50:45 +0000,http://finance.yahoo.com/r/f5a57177-ef8c-3103-aba8-b37b06b82726/etfs-with-exposure-to-fibrogen-inc-october-2-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to FibroGen, Inc. Here are 5 ETFs with the largest exposure to FGEN-US. Comparing the performance and risk of FibroGen, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more
<b>(Read more...)</b>"
FGEN,FGEN:UW,BBG0077ZBFS3,FibroGen Inc (FGEN): How Does It Impact Your Portfolio?,2017-09-30 11:17:10 +0000,https://finance.yahoo.com/news/fibrogen-inc-fgen-does-impact-111710741.html?.tsrc=rss,"If you are a shareholder in FibroGen Inc’s (NASDAQ:FGEN), or are thinking about investing in the company, knowing how it contributes to the risk and reward profile of your portfolioRead More..."
FGEN,FGEN:UW,BBG0077ZBFS3,"FibroGen, Inc. :FGEN-US: Earnings Analysis: Q2, 2017 By the Numbers : September 29, 2017",2017-09-29 13:03:46 +0000,http://finance.yahoo.com/r/2ed0e43c-9474-3082-a941-c8e5d899a4a6/fibrogen-inc-fgen-us-earnings-analysis-q2-2017-by-the-numbers-september-29-2017?yptr=yahoo&.tsrc=rss,"Categories:  Yahoo FinanceGet free summary analysis FibroGen, Inc. reports financial results for the quarter ended June 30, 2017. Highlights Summary numbers: Revenues of USD 29.00 million, Net Earnings of USD -33.18 million. Change in operating cash flow of -144.79% compared to same period last year is about the same as change in earnings, likely no significant movement ... Read more
<b>(Read more...)</b>"
FGEN,FGEN:UW,BBG0077ZBFS3,See what the IHS Markit Score report has to say about FibroGen Inc.,2017-09-28 12:04:46 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120446647.html?.tsrc=rss,Short interest is low for FGEN with fewer than 5% of shares on loan.  The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.  The net inflows of $2.42 billion over the last one-month into ETFs that hold FGEN are not among the highest of the last year and have been slowing.
FGEN,FGEN:UW,BBG0077ZBFS3,FibroGen Appoints Gerald Lema to Board of Directors,2017-09-19 20:35:35 +0000,https://finance.yahoo.com/news/fibrogen-appoints-gerald-lema-board-203535043.html?.tsrc=rss,"SAN FRANCISCO, Sept. 19, 2017-- FibroGen, Inc., a science-based biopharmaceutical company, today announced that Gerald Lema, former President of Asia Pacific at Baxter International, has been appointed ..."
FGEN,FGEN:UW,BBG0077ZBFS3,Why This Cancer Biotech Leads Pack After Hitting Record High,2017-09-13 20:33:28 +0000,http://finance.yahoo.com/r/97a23999-2e56-3f02-8cf6-23192c60a0ef/why-this-cancer-biotech-leads-pack-after-hitting-record-high?src=A00220&yptr=yahoo&.tsrc=rss,"Loxo rocketed to an all-time high on word it will present data from a Phase 1 trial in lung, thyroid, colon and solid-tumor cancers."
FGEN,FGEN:UW,BBG0077ZBFS3,Fibrogen Presents Latest Data From Phase 2b Study of Pamrevlumab in Idiopathic Pulmonary Fibrosis at European Respiratory Society (ERS) International Congress 2017,2017-09-13 11:00:00 +0000,https://finance.yahoo.com/news/fibrogen-presents-latest-data-phase-110000617.html?.tsrc=rss,"MILAN, Italy, Sept. 13, 2017-- FibroGen, Inc., a science-based biopharmaceutical company, announced today positive results from the company’ s Phase 2 b randomized, double-blind, placebo-controlled study ..."
FGEN,FGEN:UW,BBG0077ZBFS3,Is There Now An Opportunity In FibroGen Inc (FGEN)?,2017-09-06 23:14:09 +0000,https://finance.yahoo.com/news/now-opportunity-fibrogen-inc-fgen-231409459.html?.tsrc=rss,"FibroGen Inc (NASDAQ:FGEN), a pharmaceuticals, biotechnology and life sciences company based in United States, led the NasdaqGS gainers with a relatively large price hike in the past couple of weeks.Read More..."
FGEN,FGEN:UW,BBG0077ZBFS3,FibroGen Announces Pamrevlumab Oral and Poster Presentations at European Respiratory Society International Congress 2017,2017-09-05 20:05:00 +0000,https://finance.yahoo.com/news/fibrogen-announces-pamrevlumab-oral-poster-200500211.html?.tsrc=rss,"SAN FRANCISCO, Sept. 05, 2017-- FibroGen, Inc., a science-based biopharmaceutical company, today announced oral and poster presentations on pamrevlumab, an anti-CTGF monoclonal antibody in late-stage development ..."
FGEN,FGEN:UW,BBG0077ZBFS3,Analysts See 11% Upside For The Holdings of VBK,2017-08-31 13:52:47 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/7A_-b7X647U/analysts-see-11-upside-for-the-holdings-of-vbk-cm839560,Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel we have compared the trading price of each holding against the average analyst 12 month forward target price and computed the weighted average implied analyst target price for the ETF itself For the
FGEN,FGEN:UW,BBG0077ZBFS3,Biotech Movers: Red Hill Jumps After Securing Rights Sell GERD Treatment,2017-08-17 13:26:00 +0000,http://finance.yahoo.com/r/939db21d-391c-31bb-826e-c215d8853ed3/biotech-movers-red-hill-jumps-after-securing-rights-sell-gerd-treatment.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,A number of biotech-related stocks were down pre-market after announcing plans for public offerings.
FGEN,FGEN:UW,BBG0077ZBFS3,"Pre-Market Most Active for Aug 16, 2017 :  TGT, FCAU, TEVA, NEFF, URBN, BABA, YY, FGEN, AAPL, TVIX, SNAP, QQQ",2017-08-16 12:54:16 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/JbKCeiwMiU4/pre-market-most-active-for-aug-16-2017-tgt-fcau-teva-neff-urbn-baba-yy-fgen-aapl-tvix-snap-qqq-cm832621,The NASDAQ 100 Pre Market Indicator is up 9 02 to 5 916 75 The total Pre Market volume is currently 3 658 568 shares traded The following are the most active stocks for the pre market session Target Corporation TGT is 2 1 at 56 45 with 635 807 shares traded
FGEN,FGEN:UW,BBG0077ZBFS3,"FibroGen, Inc. Announces Pricing of Follow-On Offering of Common Stock",2017-08-16 03:32:11 +0000,https://finance.yahoo.com/news/fibrogen-inc-announces-pricing-offering-033211226.html?.tsrc=rss,"SAN FRANCISCO, Aug. 15, 2017-- FibroGen, Inc., a science-based biopharmaceutical company, today announced that it has priced an underwritten follow-on offering, which is expected to raise gross proceeds ..."
FGEN,FGEN:UW,BBG0077ZBFS3,"ALXN's Strengthening Patents, FOLD's Fabry Drug Approved In OZ, VBIV Surges",2017-08-16 02:01:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/UPeOCxT4xeY/alxns-strengthening-patents-folds-fabry-drug-approved-in-oz-vbiv-surges-20170816-00044,"ALXN's Strengthening Patents, FOLD's Fabry Drug Approved In OZ, VBIV Surges"
FGEN,FGEN:UW,BBG0077ZBFS3,"FibroGen, Inc. Announces Proposed Follow-On Offering of Common Stock",2017-08-14 20:26:44 +0000,https://finance.yahoo.com/news/fibrogen-inc-announces-proposed-offering-202644888.html?.tsrc=rss,"SAN FRANCISCO, Aug. 14, 2017-- FibroGen, Inc., a science-based biopharmaceutical company, today announced that it intends to offer and sell up to $300 million of its common stock in an underwritten follow-on ..."
FGEN,FGEN:UW,BBG0077ZBFS3,See what the IHS Markit Score report has to say about FibroGen Inc.,2017-08-12 12:04:48 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120448129.html?.tsrc=rss,"Short interest is low for FGEN with fewer than 5% of shares on loan.  The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.  Over the last one-month, outflows of investor capital in ETFs holding FGEN totaled $464 million."
FGEN,FGEN:UW,BBG0077ZBFS3,Edited Transcript of FGEN earnings conference call or presentation 7-Aug-17 9:00pm GMT,2017-08-12 03:45:39 +0000,https://finance.yahoo.com/news/edited-transcript-fgen-earnings-conference-025548925.html?.tsrc=rss,Q2 2017 FibroGen Inc Earnings Call
FGEN,FGEN:UW,BBG0077ZBFS3,IHS Markit Score Update: Drop in demand for ETFs holding FibroGen Inc is a negative sign for its shares,2017-08-10 12:03:33 +0000,https://finance.yahoo.com/news/ihs-markit-score-drop-demand-120333481.html?.tsrc=rss,"Short interest is low for FGEN with fewer than 5% of shares on loan.  The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.  Over the last one-month, outflows of investor capital in ETFs holding FGEN totaled $845 million."
FGEN,FGEN:UW,BBG0077ZBFS3,Strength Seen in FibroGen (FGEN): Stock Soars 48.2%,2017-08-09 14:40:53 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/YU-T_aPHvMI/strength-seen-in-fibrogen-fgen-stock-soars-482-cm829364,FibroGen Inc FGEN was a big mover last session as the company saw its shares rise over 48 on the day The move came on solid volume too with far more shares changing hands than in a normal session The stock picked up sharply from the near flat trend of 32 55 to 35 55 in the past one
FGEN,FGEN:UW,BBG0077ZBFS3,FibroGen Reaches Analyst Target Price,2017-08-09 14:34:43 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/xvClTvVbw0w/fibrogen-reaches-analyst-target-price-cm829324,In recent trading shares of FibroGen Inc Symbol FGEN have crossed above the average analyst 12 month target price of 46 67 changing hands for 49 50 share When a stock reaches the target an analyst has set the analyst logically has two ways to react downgrade on valuation or re
FGEN,FGEN:UW,BBG0077ZBFS3,"Biotech Stock Roundup: Q2 Earnings from Regeneron, Kite & More, FibroGen Up on IPF Data",2017-08-09 12:46:12 +0000,https://finance.yahoo.com/news/biotech-stock-roundup-q2-earnings-124612853.html?.tsrc=rss,Regeneron (REGN) and several other biotech companies reported Q2 earnings while FibroGen hit a 52-week high on promising idiopathic pulmonary fibrosis (IPF) data.
FGEN,FGEN:UW,BBG0077ZBFS3,Strength Seen in FibroGen (FGEN): Stock Soars 48.2%,2017-08-09 12:43:12 +0000,https://finance.yahoo.com/news/strength-seen-fibrogen-fgen-stock-124312022.html?.tsrc=rss,"FibroGen (FGEN) was a big mover last session, as the company saw its shares rise over 48% on the day amid huge volumes."
FGEN,FGEN:UW,BBG0077ZBFS3,"Gainers & Losers Of Aug.8: FGEN, CUTR, ESPR, DEPO, DERM...",2017-08-08 22:41:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/MWZu79kKr3w/gainers--losers-of-aug8-fgen-cutr-espr-depo-derm-20170808-01928,"Gainers & Losers Of Aug.8: FGEN, CUTR, ESPR, DEPO, DERM..."
FGEN,FGEN:UW,BBG0077ZBFS3,Why Did FibroGen (FGEN) Stock Hit All-Time High Today?,2017-08-08 21:36:24 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/lWUB70dJGUE/why-did-fibrogen-fgen-stock-hit-all-time-high-today-cm829075,Shares of FibroGen FGEN skyrocketed on Tuesday after the biotech company reported strong results in its most recent series of tests for its new drug that is set to help treat a fatal lung disease Just yesterday FibroGen posted a second quarter loss of 0 48 a share and revenues of 29
FGEN,FGEN:UW,BBG0077ZBFS3,"Why Ralph Lauren, LendingClub, and FibroGen Jumped Today",2017-08-08 21:36:02 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/_W_4pAYWWcs/why-ralph-lauren-lendingclub-and-fibrogen-jumped-today-cm829042,Tuesday was a letdown for investors with stocks spending much of the day in positive territory but then giving up ground toward the end of the trading session Major benchmarks fell roughly 0 15 to 0 25 with growing concern among some market participants that a long awaited
FGEN,FGEN:UW,BBG0077ZBFS3,Why FibroGen Inc Skyrocketed Higher Today,2017-08-08 20:38:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/kLJ3L2Zppeo/why-fibrogen-inc-skyrocketed-higher-today-cm829022,What happened FibroGen NASDAQ FGEN is up nearly 50 at 1 10 p m Tuesday after releasing positive data from its phase 2 trial testing pamrevlumab in patients with a lung disease called idiopathic pulmonary fibrosis IPF So what To see how well the drug was working
FGEN,FGEN:UW,BBG0077ZBFS3,"Health Care Sector Update for 08/08/2017: FATE,FGEN,BIOA",2017-08-08 20:35:17 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/T8UeBTpccY4/health-care-sector-update-for-08082017-fatefgenbioa-cm829028,Top Health Care StocksTop Health Care Stocks JNJ 0 47 JNJ 0 47 PFE 0 03 PFE 0 03 ABT 0 81 ABT 0 81 MRK 0 83 MRK 0 83 AMGN 0 51 AMGN 0 51 Health care stocks have kept adding to their prior losses today with the NYSE Health Care Index falling just less than 0 5 this afternoon
FGEN,FGEN:UW,BBG0077ZBFS3,"Why Ralph Lauren, LendingClub, and FibroGen Jumped Today",2017-08-08 20:20:00 +0000,http://finance.yahoo.com/r/45e2242e-4c1a-3959-a42d-832ca9b6e5c3/why-ralph-lauren-lendingclub-and-fibrogen-jumped-t.aspx?yptr=yahoo&.tsrc=rss,"Even though the market fell, these stocks gained ground. Find out why."
FGEN,FGEN:UW,BBG0077ZBFS3,Why Did FibroGen (FGEN) Stock Hit All-Time High Today?,2017-08-08 19:06:07 +0000,https://finance.yahoo.com/news/why-did-fibrogen-fgen-stock-190607474.html?.tsrc=rss,Shares of FibroGen (FGEN) skyrocketed on Tuesday after the biotech company reported strong results in its most recent series of tests for its new drug that is set to help treat a fatal lung disease.
FGEN,FGEN:UW,BBG0077ZBFS3,Why FibroGen Inc Skyrocketed Higher Today,2017-08-08 18:37:00 +0000,http://finance.yahoo.com/r/8de38261-37f4-3e43-b765-547685e82c16/why-fibrogen-inc-skyrocketed-higher-today.aspx?yptr=yahoo&.tsrc=rss,Positive phase 2 data for the company&apos;s lung drug increases the biotech&apos;s value.
FGEN,FGEN:UW,BBG0077ZBFS3,"Health Care Sector Update for 08/08/2017: DEPO,FGEN,BIOA",2017-08-08 18:34:56 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/jTllgcK2ozo/health-care-sector-update-for-08082017-depofgenbioa-cm828958,Top Health Care StocksTop Health Care Stocks JNJ 0 38 JNJ 0 38 PFE 0 29 PFE 0 29 ABT 0 47 ABT 0 47 MRK 0 59 MRK 0 59 AMGN 0 17 AMGN 0 17 Health care stocks were little changed in recent trading with the NYSE Health Care Index were falling less than 0 1 this afternoon while
FGEN,FGEN:UW,BBG0077ZBFS3,Biotech FibroGen soars more than 50% on positive lung disease treatment study,2017-08-08 15:07:10 +0000,http://finance.yahoo.com/r/f38fb7c6-6f67-375e-99a9-f41585cc8bf3/104639611?__source=yahoo%7Cfinance%7Cheadline%7Cheadline%7Cstory&par=yahoo&doc=104639611&yptr=yahoo&.tsrc=rss,The biotech company's drug pamrevlumab successfully completed a mid-stage Food and Drug Administration test.
FGEN,FGEN:UW,BBG0077ZBFS3,Biotech FibroGen soars more than 50% on positive lung disease treatment study,2017-08-08 15:07:10 +0000,https://finance.yahoo.com/news/biotech-fibrogen-soars-more-50-150710945.html?.tsrc=rss,The biotech company&apos;s drug pamrevlumab successfully completed a mid-stage Food and Drug Administration test.
FGEN,FGEN:UW,BBG0077ZBFS3,Why Fibrogen Shares Are Exploding,2017-08-08 14:55:04 +0000,https://finance.yahoo.com/news/why-fibrogen-shares-exploding-145504060.html?.tsrc=rss,"When FibroGen released its most recent quarterly results after the markets closed on Monday, its was not the most important news that broke."
FGEN,FGEN:UW,BBG0077ZBFS3,FibroGen shares surge 49% on positive mid-stage trial for pulmonary fibrosis therapy,2017-08-08 14:54:20 +0000,http://finance.yahoo.com/r/217884c3-217d-3d03-a62c-105beb7a88dc/Story.aspx?guid=2040C6DE-AD38-4148-B4B9-3E7CD38FEC74&siteid=yhoof2&yptr=yahoo&.tsrc=rss,FibroGen Inc. shares surged 48.6% in extremely heavy morning trade on Tuesday after the biopharmaceutical company released positive results for a mid-stage trial of its idiopathic pulmonary fibrosis therapy. ...
FGEN,FGEN:UW,BBG0077ZBFS3,Biotech Movers: FibroGen Leaps on Results for Pulmonary Fibrosis Study,2017-08-08 13:29:00 +0000,http://finance.yahoo.com/r/cb4843a6-a890-339a-b27c-9737c1db833e/biotech-movers-fibrogen-leaps-on-results-for-pulmonary-fibrosis-study.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,"FibroGen, Depomed and Valeant were among the biotech stock movers in premarket trading on Aug. 8."
FGEN,FGEN:UW,BBG0077ZBFS3,"Pre-Market Most Active for Aug 8, 2017 :  VRX, ENDP, TEVA, ABB, FGEN, QQQ, INVA, CAR, KORS, NVDA, HTZ, PAGP",2017-08-08 12:53:32 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/um4N-O5f0N0/pre-market-most-active-for-aug-8-2017-vrx-endp-teva-abb-fgen-qqq-inva-car-kors-nvda-htz-pagp-cm828565,The NASDAQ 100 Pre Market Indicator is down 1 37 to 5 933 36 The total Pre Market volume is currently 7 622 229 shares traded The following are the most active stocks for the pre market session Valeant Pharmaceuticals International Inc VRX is 1 37 at 16 74
FGEN,FGEN:UW,BBG0077ZBFS3,FibroGen Inc. (FGEN) Has Soared To A New High On Phase 2 Study News,2017-08-08 09:35:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/jEXRORzdMTU/fibrogen-inc-fgen-has-soared-to-a-new-high-on-phase-2-study-news-20170808-00969,FibroGen Inc. (FGEN) Has Soared To A New High On Phase 2 Study News
FGEN,FGEN:UW,BBG0077ZBFS3,FibroGen reports 2Q loss,2017-08-08 03:00:58 +0000,https://finance.yahoo.com/news/fibrogen-reports-2q-loss-220019780.html?.tsrc=rss,The San Francisco-based company said it had a loss of 48 cents per share. The results missed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for ...
FGEN,FGEN:UW,BBG0077ZBFS3,FibroGen Announces Positive Topline Results from Phase 2 Study of Pamrevlumab in Idiopathic Pulmonary Fibrosis,2017-08-07 20:50:50 +0000,https://finance.yahoo.com/news/fibrogen-announces-positive-topline-results-205050467.html?.tsrc=rss,"Meets Primary Endpoint with Statistical Significance. Management to discuss results on today’ s quarterly financial results conference call. SAN FRANCISCO, Aug. 07, 2017-- FibroGen, Inc., a science-based ..."
FGEN,FGEN:UW,BBG0077ZBFS3,FibroGen Reports Second Quarter 2017 Financial Results,2017-08-07 20:39:11 +0000,https://finance.yahoo.com/news/fibrogen-reports-second-quarter-2017-203911115.html?.tsrc=rss,"Company Announces Positive Topline Results from Phase 2 Study in IPF. Conference Call and Webcast to be Held Today at 5:00 p.m. Eastern Time/2: 00 p.m. SAN FRANCISCO, Aug. 07, 2017-- FibroGen, Inc., a ..."
FGEN,FGEN:UW,BBG0077ZBFS3,"Investor Network: FibroGen, Inc. to Host Earnings Call",2017-08-07 16:10:00 +0000,https://finance.yahoo.com/news/investor-network-fibrogen-inc-host-161000616.html?.tsrc=rss,"NEW YORK, NY / ACCESSWIRE / August 7, 2017 / FibroGen, Inc. (NASDAQ: FGEN ) will be discussing their earnings results in their Q2 Earnings Call to be held on Monday, August 7, 2017 at 5:00 PM Eastern Time. ..."
FGEN,FGEN:UW,BBG0077ZBFS3,Should You Buy FibroGen (FGEN) Ahead of Earnings?,2017-08-03 14:02:29 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/JPQoCPVBXNc/should-you-buy-fibrogen-fgen-ahead-of-earnings-cm826423,Investors are always looking for stocks that are poised to beat at earnings season and FibroGen Inc FGEN may be one such company The firm has earnings coming up pretty soon and events are shaping up quite nicely for their report That is because FibroGen is seeing favorable earnings
FGEN,FGEN:UW,BBG0077ZBFS3,Should You Buy FibroGen (FGEN) Ahead of Earnings?,2017-08-03 12:51:12 +0000,https://finance.yahoo.com/news/buy-fibrogen-fgen-ahead-earnings-125112294.html?.tsrc=rss,"Investors are always looking for stocks that are poised to beat at earnings season and FibroGen, Inc. (FGEN) may be one such company."
FGEN,FGEN:UW,BBG0077ZBFS3,"FibroGen to Report Second Quarter Financial Results on Monday, August 7, 2017",2017-07-31 23:00:00 +0000,https://finance.yahoo.com/news/fibrogen-report-second-quarter-financial-230000888.html?.tsrc=rss,"SAN FRANCISCO, July 31, 2017-- FibroGen, Inc., a science-based biopharmaceutical company, today announced that it will report financial results for the second quarter of 2017 on Monday, August 7, 2017, ..."
FGEN,FGEN:UW,BBG0077ZBFS3,FibroGen Granted Orphan Drug Designation for Pamrevlumab in the Treatment of Pancreatic Cancer,2017-06-22 02:10:13 +0000,https://finance.yahoo.com/news/fibrogen-granted-orphan-drug-designation-021013499.html?.tsrc=rss,"SAN FRANCISCO, June 21, 2017-- FibroGen, Inc., a science-based biopharmaceutical company, today announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation status to pamrevlumab, ..."
FGEN,FGEN:UW,BBG0077ZBFS3,FibroGen's Pamrevlumab Gets Orphan Drug Designation To Treat Pancreatic Cancer,2017-06-22 00:37:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/AZsiQoaIQQ0/fibrogens-pamrevlumab-gets-orphan-drug-designation-to-treat-pancreatic-cancer-20170622-00007,FibroGen's Pamrevlumab Gets Orphan Drug Designation To Treat Pancreatic Cancer
FGEN,FGEN:UW,BBG0077ZBFS3,"About FibroGen, Inc.FibroGen to Present at the Goldman Sachs 38th Annual Global Healthcare Conference",2017-06-13 11:00:00 +0000,https://finance.yahoo.com/news/fibrogen-inc-fibrogen-present-goldman-110000420.html?.tsrc=rss,"SAN FRANCISCO, June 13, 2017-- FibroGen, Inc., a science-based biopharmaceutical company, today announced that Chief Executive Officer Thomas B. Neff will participate in a Fireside Chat at the Goldman ..."
FGEN,FGEN:UW,BBG0077ZBFS3,European Patent Office Maintains FibroGen Patent Relating to Hypoxia-Inducible Factor (HIF) Prolyl Hydroxylase Inhibitor Technology,2017-06-05 11:00:00 +0000,https://finance.yahoo.com/news/european-patent-office-maintains-fibrogen-110000121.html?.tsrc=rss,"SAN FRANCISCO, June 05, 2017-- FibroGen, Inc., a science-based biopharmaceutical company, announced today that a FibroGen European patent relating to the therapeutic use of certain small molecule inhibitors ..."
FGEN,FGEN:UW,BBG0077ZBFS3,"ETFs with exposure to FibroGen, Inc. : June 2, 2017",2017-06-02 18:07:49 +0000,http://finance.yahoo.com/r/68d3d2cb-3b80-3057-99ec-ec89913ef0e7/etfs-with-exposure-to-fibrogen-inc-june-2-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to FibroGen, Inc. Here are 5 ETFs with the largest exposure to FGEN-US. Comparing the performance and risk of FibroGen, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more
<b>(Read more...)</b>"
FGEN,FGEN:UW,BBG0077ZBFS3,"FibroGen, Inc. breached its 50 day moving average in a Bullish Manner : FGEN-US : June 2, 2017",2017-06-02 12:41:20 +0000,http://finance.yahoo.com/r/73db2ab0-151e-3b3b-a118-d8c2e94db882/fibrogen-inc-breached-its-50-day-moving-average-in-a-bullish-manner-fgen-us-june-2-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceClick here to see latest analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for FibroGen, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average ... Read more
<b>(Read more...)</b>"
FGEN,FGEN:UW,BBG0077ZBFS3,Edited Transcript of FGEN earnings conference call or presentation 9-May-17 8:30pm GMT,2017-05-25 01:01:13 +0000,https://finance.yahoo.com/news/edited-transcript-fgen-earnings-conference-024535278.html?.tsrc=rss,Q1 2017 FibroGen Inc Earnings Call
FGEN,FGEN:UW,BBG0077ZBFS3,"ETFs with exposure to FibroGen, Inc. : May 22, 2017",2017-05-22 17:39:42 +0000,http://finance.yahoo.com/r/f6687406-4b26-3b9a-895c-714c6ef2c2a8/etfs-with-exposure-to-fibrogen-inc-may-22-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to FibroGen, Inc. Here are 5 ETFs with the largest exposure to FGEN-US. Comparing the performance and risk of FibroGen, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more
<b>(Read more...)</b>"
FGEN,FGEN:UW,BBG0077ZBFS3,"FibroGen, Inc. :FGEN-US: Earnings Analysis: Q1, 2017 By the Numbers : May 19, 2017",2017-05-19 13:47:29 +0000,http://finance.yahoo.com/r/825fa7b8-158d-334d-846c-669751a37b9c/fibrogen-inc-fgen-us-earnings-analysis-q1-2017-by-the-numbers-may-19-2017?yptr=yahoo&.tsrc=rss,"Categories:  Yahoo FinanceGet free summary analysis FibroGen, Inc. reports financial results for the quarter ended March 31, 2017. We analyze the earnings along side the following peers of FibroGen, Inc. – Illumina, Inc., Acceleron Pharma Inc, Accelerate Diagnostics, Inc. and Harvard Bioscience, Inc. (ILMN-US, XLRN-US, AXDX-US and HBIO-US) that have also reported for this period. Highlights Summary ... Read more
<b>(Read more...)</b>"
FGEN,FGEN:UW,BBG0077ZBFS3,Akebia Secures Exclusive Access to U.S. Dialysis Patients With Vifor-Fresenius Pact,2017-05-15 20:05:00 +0000,http://finance.yahoo.com/r/9e3891f9-c1e6-398d-b426-792148ee63e3/akebia-secures-exclusive-access-to-u-s-dialysis-patients-with-vifor-fresenius-pact.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,"Monday's licensing deal is a nice win for Akebia because Fresenius is the largest dialysis provider in North America, serving approximately 40% of dialysis patients in the U.S."
FGEN,FGEN:UW,BBG0077ZBFS3,Edited Transcript of FGEN earnings conference call or presentation 9-May-17 8:30pm GMT,2017-05-11 01:25:44 +0000,http://finance.yahoo.com/news/edited-transcript-fgen-earnings-conference-024535278.html?.tsrc=rss,Q1 2017 FibroGen Inc Earnings Call
FGEN,FGEN:UW,BBG0077ZBFS3,FibroGen Reports First Quarter 2017 Financial Results,2017-05-09 20:02:00 +0000,http://finance.yahoo.com/news/fibrogen-reports-first-quarter-2017-200200613.html?.tsrc=rss,"SAN FRANCISCO, May 09, 2017-- FibroGen, Inc., a science-based biopharmaceutical company, today reported financial results for the first quarter of 2017 and provided an update on the company’ s recent developments.. ..."
FGEN,FGEN:UW,BBG0077ZBFS3,"Investor Network: FibroGen, Inc. to Host Earnings Call",2017-05-09 19:00:00 +0000,http://finance.yahoo.com/news/investor-network-fibrogen-inc-host-190000234.html?.tsrc=rss,"NEW YORK, NY / ACCESSWIRE / May 9, 2017 / FibroGen, Inc. (NASDAQ: FGEN ) will be discussing their earnings results in their Q1 Earnings Call to be held May 9, 2017 at 4:30 PM Eastern Time. To listen to ..."
FGEN,FGEN:UW,BBG0077ZBFS3,Mylan  (MYL) Q1 Earnings: Will the Stock Pull a Surprise?,2017-05-05 23:24:32 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/xAFKwpCiW3A/mylan-myl-q1-earnings-will-the-stock-pull-a-surprise-cm785335,Mylan N V MYL is scheduled to report first quarter 2017 results on May 10 before the market opens The company s performance has been mixed so far having beaten earnings estimates in three of the trailing four quarters and missing once Overall it has delivered an average positive
FGEN,FGEN:UW,BBG0077ZBFS3,Mylan (MYL) Q1 Earnings: Will the Stock Pull a Surprise?,2017-05-05 21:22:09 +0000,http://finance.yahoo.com/news/mylan-myl-q1-earnings-stock-212209422.html?.tsrc=rss,"Mylan N.V. (MYL) is scheduled to report first-quarter 2017 results on May 10, before the market opens."
FGEN,FGEN:UW,BBG0077ZBFS3,What's in the Cards for Repros (RPRX) this Earnings Season?,2017-05-05 17:25:28 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Zi9kZKqPlRc/whats-in-the-cards-for-repros-rprx-this-earnings-season-cm785069,Repros Therapeutics Inc RPRX is expected to report first quarter 2017 results this month Let s see how things are shaping up for this quarter Repros Therapeutics share price has decreased 28 8 year to date while the Zacks classified Medical Biomed Genetics industry gained 4
FGEN,FGEN:UW,BBG0077ZBFS3,What&apos;s in the Cards for Repros (RPRX) this Earnings Season?,2017-05-05 15:02:03 +0000,http://finance.yahoo.com/news/apos-cards-repros-rprx-earnings-150203766.html?.tsrc=rss,Repros Therapeutics Inc. (RPRX) is expected to report first-quarter 2017 results this month. Let&apos;s see how things are shaping up for this quarter.
FGEN,FGEN:UW,BBG0077ZBFS3,"Should You Sell FibroGen, Inc (FGEN) Before Earnings?",2017-05-05 14:24:52 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/aO9lft_mzAU/should-you-sell-fibrogen-inc-fgen-before-earnings-cm784818,Investors are always looking for stocks that are poised to beat at earnings season and FibroGen Inc FGEN 160 may be one such company The firm has earnings coming up pretty soon and events are shaping up quite nicely for their report That is because FibroGen is seeing favorable
FGEN,FGEN:UW,BBG0077ZBFS3,"Should You Sell FibroGen, Inc (FGEN) Before Earnings?",2017-05-05 12:45:12 +0000,http://finance.yahoo.com/news/sell-fibrogen-inc-fgen-earnings-124512537.html?.tsrc=rss,"FibroGen, Inc (FGEN) stock looks lucrative Before Earnings on the back of its solid zacks rank and positive earnings ESP."
FGEN,FGEN:UW,BBG0077ZBFS3,Is Horizon Pharma (HZNP) Poised for a Beat in Q1 Earnings?,2017-05-04 23:10:29 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/fldFu8nU11A/is-horizon-pharma-hznp-poised-for-a-beat-in-q1-earnings-cm784628,Horizon Pharma plc HZNP is scheduled to report first quarter 2017 results before the opening bell on May 8 Horizon s performance has been dismal with the company missing earnings estimates in the four trailing quarters Overall the company has an average negative earnings surprise of 11
FGEN,FGEN:UW,BBG0077ZBFS3,Is Endo (ENDP) Poised for a Beat This Earnings Season?,2017-05-04 23:09:59 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/7QVZSNAJgas/is-endo-endp-poised-for-a-beat-this-earnings-season-cm784623,Endo International plc ENDP is scheduled to report first quarter 2017 results on May 9 before the opening bell Endo posted a positive surprise in each of the trailing four quarters with an average positive surprise of 12 7 Last quarter the company delivered a positive earnings surprise
FGEN,FGEN:UW,BBG0077ZBFS3,Is Endo (ENDP) Poised for a Beat This Earnings Season?,2017-05-04 21:32:09 +0000,http://finance.yahoo.com/news/endo-endp-poised-beat-earnings-213209617.html?.tsrc=rss,"Endo International plc (ENDP) is scheduled to report first-quarter 2017 results on May 9, before the opening bell."
FGEN,FGEN:UW,BBG0077ZBFS3,Is Horizon Pharma (HZNP) Poised for a Beat in Q1 Earnings?,2017-05-04 21:21:09 +0000,http://finance.yahoo.com/news/horizon-pharma-hznp-poised-beat-212109540.html?.tsrc=rss,Horizon Pharma plc (HZNP) is scheduled to report first-quarter 2017 results before the opening bell on May 8.
FGEN,FGEN:UW,BBG0077ZBFS3,Can Ligand (LGND) Spring a Surprise this Earnings Season?,2017-05-04 16:15:09 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/RhxvkGeYlAc/can-ligand-lgnd-spring-a-surprise-this-earnings-season-cm784212,Ligand Pharmaceuticals Incorporated LGND is scheduled to report first quarter 2017 results on May 9 after the market closes Ligand s earnings history has been disappointing as it missed expectations in three of the last four quarters and beat estimates in one Overall the company had
FGEN,FGEN:UW,BBG0077ZBFS3,Arena Pharmaceuticals (ARNA) Q1 Earnings: What's in Store?,2017-05-04 16:14:29 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/T5reVbvTxvo/arena-pharmaceuticals-arna-q1-earnings-whats-in-store-cm784203,Arena Pharmaceuticals Inc ARNA is expected to report first quarter 2017 on May 9 after market closes The company delivered a positive earnings surprise of 277 78 in the last quarter Over the four trailing quarters it had an average positive surprise of 79 09 Let s see how things
FGEN,FGEN:UW,BBG0077ZBFS3,What's in the Cards for Allergan (AGN) this Earnings Season?,2017-05-04 16:14:14 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ICPAHbW5lzE/whats-in-the-cards-for-allergan-agn-this-earnings-season-cm784196,Allergan plc AGN will report first quarter 2017 earnings on May 9 before the market opens Last quarter the company delivered a positive earnings surprise of 2 90 Allergan s share price is up 16 1 this year so far outperforming the 1 decline witnessed by the Zacks
FGEN,FGEN:UW,BBG0077ZBFS3,What&apos;s in the Cards for Allergan (AGN) this Earnings Season?,2017-05-04 14:34:02 +0000,http://finance.yahoo.com/news/apos-cards-allergan-agn-earnings-143402890.html?.tsrc=rss,"Allergan plc (AGN) will be reporting first-quarter 2017 earnings result on May 9, before the market opens."
FGEN,FGEN:UW,BBG0077ZBFS3,Arena Pharmaceuticals (ARNA) Q1 Earnings: What&apos;s in Store?,2017-05-04 14:32:02 +0000,http://finance.yahoo.com/news/arena-pharmaceuticals-arna-q1-earnings-143202821.html?.tsrc=rss,"Arena Pharmaceuticals, Inc. (ARNA) is expected to report first-quarter 2017 on May 9, after market closes."
FGEN,FGEN:UW,BBG0077ZBFS3,Can Ligand (LGND) Spring a Surprise this Earnings Season?,2017-05-04 14:29:02 +0000,http://finance.yahoo.com/news/ligand-lgnd-spring-surprise-earnings-142902520.html?.tsrc=rss,"Ligand Pharmaceuticals Incorporated (LGND) is scheduled to report first-quarter 2017 results on May 9, after the market closes."
FGEN,FGEN:UW,BBG0077ZBFS3,What's in Store for Mallinckrodt (MNK) This Earnings Season?,2017-05-03 23:10:47 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/P2vG1nwYXO0/whats-in-store-for-mallinckrodt-mnk-this-earnings-season-cm783827,Mallinckrodt plc MNK is set to report first quarter fiscal 2017 results on May 8 The company s track record has been impressive so far Mallinckrodt delivered a positive average earnings surprise of 8 7 in the last four trailing quarters Let s see how things are shaping up for
FGEN,FGEN:UW,BBG0077ZBFS3,What's in the Cards for Inovio (INO) This Earnings Season?,2017-05-03 21:09:49 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/zxJYDiyBuOo/whats-in-the-cards-for-inovio-ino-this-earnings-season-cm783820,Inovio Pharmaceuticals Inc INO is scheduled to report first quarter 2017 results after market closes The company incurred a wider than expected loss in the last quarter In the last year Inovio s shares underperformed the Zacks classified Medical Biomed Genetics industry The stock
FGEN,FGEN:UW,BBG0077ZBFS3,What's in Store for Adverum (ADVM) in Q1 Earnings?,2017-05-03 21:09:35 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/LP-3C91HSfE/whats-in-store-for-adverum-advm-in-q1-earnings-cm783816,Adverum Biotechnologies Inc ADVM is expected to report first quarter 2017 results later this month In the last reported quarter Adverum posted a negative surprise of 8 In fact the company has a dismal track record with the company missing estimates in three of the last four
FGEN,FGEN:UW,BBG0077ZBFS3,What to Expect from Epizyme (EPZM) This Earnings Season?,2017-05-03 21:09:23 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Rti2IZ5TIIY/what-to-expect-from-epizyme-epzm-this-earnings-season-cm783813,Epizyme Inc EPZM is scheduled to report first quarter 2017 results on May 8 before the opening bell Last quarter the company recorded a positive earnings surprise of 6 25 In fact Epizyme s track record has been strong with the company surpassing expectations in all of the four
FGEN,FGEN:UW,BBG0077ZBFS3,What&apos;s in Store for Mallinckrodt (MNK) This Earnings Season?,2017-05-03 20:50:08 +0000,http://finance.yahoo.com/news/apos-store-mallinckrodt-mnk-earnings-205008880.html?.tsrc=rss,Mallinckrodt plc (MNK) is set to report first-quarter fiscal 2017 results on May 8.
FGEN,FGEN:UW,BBG0077ZBFS3,Kite Pharma (KITE) Q1 Earnings: Is a Surprise in the Cards?,2017-05-03 20:48:24 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/7g9r-PChTXQ/kite-pharma-kite-q1-earnings-is-a-surprise-in-the-cards-cm783761,Kite Pharma Inc KITE is expected to report first quarter 2017 results on May 8 before market opens Last quarter the company delivered a positive earnings surprise of 2 86 Kite Pharma s shares are up 82 so far this year This compares favorably with the 5 5 increase registered by
FGEN,FGEN:UW,BBG0077ZBFS3,What to Expect from Epizyme (EPZM) This Earnings Season?,2017-05-03 20:36:08 +0000,http://finance.yahoo.com/news/expect-epizyme-epzm-earnings-season-203608728.html?.tsrc=rss,"Epizyme, Inc. (EPZM) is scheduled to report first-quarter 2017 results on May 8, before the opening bell."
FGEN,FGEN:UW,BBG0077ZBFS3,What&apos;s in Store for Adverum (ADVM) in Q1 Earnings?,2017-05-03 20:34:08 +0000,http://finance.yahoo.com/news/apos-store-adverum-advm-q1-203408396.html?.tsrc=rss,"Adverum Biotechnologies, Inc (ADVM) is expected to report first-quarter 2017 results later this month."
FGEN,FGEN:UW,BBG0077ZBFS3,What&apos;s in the Cards for Inovio (INO) This Earnings Season?,2017-05-03 20:28:08 +0000,http://finance.yahoo.com/news/apos-cards-inovio-ino-earnings-202808273.html?.tsrc=rss,"Inovio Pharmaceuticals, Inc. (INO) is scheduled to report first-quarter 2017 results, after market closes. The company incurred wider-than-expected loss in the last quarter."
FGEN,FGEN:UW,BBG0077ZBFS3,Jazz Pharma (JAZZ) Q1 Earnings: Stock Likely to Disappoint?,2017-05-03 19:51:37 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/v4pnidxCQ0c/jazz-pharma-jazz-q1-earnings-stock-likely-to-disappoint-cm783686,Jazz Pharmaceuticals plc JAZZ is scheduled to report first quarter 2017 results on May 9 after the market closes Jazz s shares have significantly outperformed the Zacks classified Medical Drugs industry so far this year Specifically the stock gained 46 4 during the period while
FGEN,FGEN:UW,BBG0077ZBFS3,Puma Biotechnology (PBYI) Q1 Earnings: Stock to Disappoint?,2017-05-03 19:51:25 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/zb9GA9O8h08/puma-biotechnology-pbyi-q1-earnings-stock-to-disappoint-cm783680,Puma Biotechnology Inc PBYI is expected to report first quarter 2017 results later this month The company s earnings track record is disappointing as it missed estimates in three of the trailing four quarters and met expectations in one The company had an average negative surprise of 3 23
FGEN,FGEN:UW,BBG0077ZBFS3,Kite Pharma (KITE) Q1 Earnings: Is a Surprise in the Cards?,2017-05-03 19:36:07 +0000,http://finance.yahoo.com/news/kite-pharma-kite-q1-earnings-193607884.html?.tsrc=rss,"Kite Pharma, Inc. (KITE) is expected to report first-quarter 2017 results on May 8 before the market opens."
FGEN,FGEN:UW,BBG0077ZBFS3,Puma Biotechnology (PBYI) Q1 Earnings: Stock to Disappoint?,2017-05-03 14:44:02 +0000,http://finance.yahoo.com/news/puma-biotechnology-pbyi-q1-earnings-144402538.html?.tsrc=rss,"Puma Biotechnology, Inc. (PBYI) is expected to report first-quarter 2017 results later this month."
FGEN,FGEN:UW,BBG0077ZBFS3,Jazz Pharma (JAZZ) Q1 Earnings: Stock Likely to Disappoint?,2017-05-03 14:35:02 +0000,http://finance.yahoo.com/news/jazz-pharma-jazz-q1-earnings-143502669.html?.tsrc=rss,"Jazz Pharmaceuticals plc (JAZZ) is scheduled to report first-quarter 2017 results on May 9, after the market closes."
FGEN,FGEN:UW,BBG0077ZBFS3,"FibroGen to Report First Quarter Financial Results on May 9, 2017",2017-05-03 11:00:00 +0000,http://finance.yahoo.com/news/fibrogen-report-first-quarter-financial-110000269.html?.tsrc=rss,"SAN FRANCISCO, May 03, 2017-- FibroGen, Inc., a science-based biopharmaceutical company, today announced that it will report first quarter financial results on Tuesday, May 9, 2017, after market close, ..."
FGEN,FGEN:UW,BBG0077ZBFS3,What's in Store for Catalyst (CPRX) Stock in Q1 Earnings?,2017-05-03 00:26:10 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/wsWHPXcbGxg/whats-in-store-for-catalyst-cprx-stock-in-q1-earnings-cm783131,Catalyst Pharmaceuticals Inc CPRX is expected to report first quarter 2017 results on May 11 160 Last quarter the company recorded a positive earnings surprise of 16 67 Also it topped expectations in all of the last four quarters with average positive surprise of 14 59 Catalyst
FGEN,FGEN:UW,BBG0077ZBFS3,What&apos;s in Store for Catalyst (CPRX) Stock in Q1 Earnings?,2017-05-02 22:40:10 +0000,http://finance.yahoo.com/news/apos-store-catalyst-cprx-stock-224010875.html?.tsrc=rss,"Catalyst Pharmaceuticals, Inc. (CPRX) is expected to report first-quarter 2017 results on May 11."
FGEN,FGEN:UW,BBG0077ZBFS3,Will Intrexon (XON) Pull Off a Surprise in Q1 Earnings?,2017-05-02 22:38:10 +0000,http://finance.yahoo.com/news/intrexon-xon-pull-off-surprise-223810280.html?.tsrc=rss,Intrexon Corporation (XON) is expected to report first-quarter 2017 results on May 9.
FGEN,FGEN:UW,BBG0077ZBFS3,GW Pharmaceuticals (GWPH) Q2 Earnings: What to Expect?,2017-05-02 22:28:10 +0000,http://finance.yahoo.com/news/gw-pharmaceuticals-gwph-q2-earnings-222810870.html?.tsrc=rss,GW Pharmaceuticals plc (GWPH) is expected to report second-quarter fiscal 2017 results on May 4.
FGEN,FGEN:UW,BBG0077ZBFS3,What's in the Cards for ACADIA (ACAD) this Earnings Season?,2017-05-02 14:30:44 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/vtZDwwfOXYo/whats-in-the-cards-for-acadia-acad-this-earnings-season-cm782692,ACADIA Pharmaceuticals Inc ACAD is expected to report first quarter 2017 results on May 4 The company s track record has been dismal Evidently ACADIA missed estimates in three of the trailing four quarters bringing the average negative surprise to 13 67 In the last reported
FGEN,FGEN:UW,BBG0077ZBFS3,What&apos;s in the Cards for ACADIA (ACAD) this Earnings Season?,2017-05-02 13:11:01 +0000,http://finance.yahoo.com/news/apos-cards-acadia-acad-earnings-131101670.html?.tsrc=rss,ACADIA Pharmaceuticals Inc. (ACAD) is expected to report first-quarter 2017 results on May 4.
FGEN,FGEN:UW,BBG0077ZBFS3,What's in Store for Zoetis (ZTS) Stock This Earnings Season?,2017-05-01 22:26:42 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/C2LMpBVjJWQ/whats-in-store-for-zoetis-zts-stock-this-earnings-season-cm782327,Zoetis Inc ZTS is scheduled to report first quarter 2017 results on May 4 before the market opens In fact the company has been seen to consistently beat earnings expectations Zoetis earnings surpassed expectations in each of the last four quarters with an average positive surprise
FGEN,FGEN:UW,BBG0077ZBFS3,Radius Health (RDUS) Q1 Earnings: What's in Store?,2017-05-01 22:26:29 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/y1PscfZlKyQ/radius-health-rdus-q1-earnings-whats-in-store-cm782325,Radius Health Inc RDUS is scheduled to report first quarter 2017 financial results on May 3 Radius shares underperformed the Medical Drugs industry in the last six months The stock lost 17 6 during this time period as compared to a gain of 10 1 for the industry Radius Health
FGEN,FGEN:UW,BBG0077ZBFS3,Radius Health (RDUS) Q1 Earnings: What&apos;s in Store?,2017-05-01 20:14:08 +0000,http://finance.yahoo.com/news/radius-health-rdus-q1-earnings-201408553.html?.tsrc=rss,"Radius Health, Inc. (RDUS) is scheduled to report first-quarter 2017 financial results on May 3."
FGEN,FGEN:UW,BBG0077ZBFS3,What&apos;s in Store for Zoetis (ZTS) Stock This Earnings Season?,2017-05-01 20:06:08 +0000,http://finance.yahoo.com/news/apos-store-zoetis-zts-stock-200608213.html?.tsrc=rss,Zoetis Inc. (ZTS) is scheduled to report first-quarter 2017 results on May 4.
FGEN,FGEN:UW,BBG0077ZBFS3,What to Expect from Endocyte (ECYT) Stock for Q1 Earnings?,2017-05-01 20:03:08 +0000,http://finance.yahoo.com/news/expect-endocyte-ecyt-stock-q1-200308521.html?.tsrc=rss,"Endocyte, Inc (ECYT) is expected to report first-quarter 2017 results on May 3."
FGEN,FGEN:UW,BBG0077ZBFS3,Is Intercept (ICPT) Poised for a Beat This Earnings Season?,2017-04-28 22:19:10 +0000,http://finance.yahoo.com/news/intercept-icpt-poised-beat-earnings-221910782.html?.tsrc=rss,Is Intercept (ICPT) Poised for a Beat this Earnings Season?
FGEN,FGEN:UW,BBG0077ZBFS3,What to Expect from Keryx (KERX) Stock This Earnings Season?,2017-04-28 22:07:10 +0000,http://finance.yahoo.com/news/expect-keryx-kerx-stock-earnings-220710612.html?.tsrc=rss,"Keryx Biopharmaceuticals, Inc. (KERX) is expected to report first-quarter 2017 results on May 4."
FGEN,FGEN:UW,BBG0077ZBFS3,What's in the Cards for Merrimack (MACK) in Q1 Earnings?,2017-04-27 18:27:25 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/2Z6E5sJqIqA/whats-in-the-cards-for-merrimack-mack-in-q1-earnings-cm780546,Merrimack Pharmaceuticals Inc MACK is expected to report first quarter 2017 results around May 1 Last quarter Merrimack missed bottom line expectations by 13 64 Merrimack s share price decreased 18 4 year to date against the Zacks classified Medical Biomedical and Genetics industry
FGEN,FGEN:UW,BBG0077ZBFS3,What&apos;s in the Cards for Merrimack (MACK) in Q1 Earnings?,2017-04-27 16:03:04 +0000,http://finance.yahoo.com/news/apos-cards-merrimack-mack-q1-160304312.html?.tsrc=rss,"Merrimack Pharmaceuticals, Inc. (MACK) is expected to report first-quarter 2017 results around May 1. Last quarter, Merrimack missed bottom line expectations"
FGEN,FGEN:UW,BBG0077ZBFS3,What to Expect from Prothena (PRTA) This Earnings Season?,2017-04-26 20:19:08 +0000,http://finance.yahoo.com/news/expect-prothena-prta-earnings-season-201908476.html?.tsrc=rss,Prothena Corporation plc (PRTA) is expected to report first-quarter 2017 results early next month.
FGEN,FGEN:UW,BBG0077ZBFS3,What Awaits Aerie Pharmaceuticals (AERI) in Q1 Earnings?,2017-04-26 15:10:25 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/7JpijALQScg/what-awaits-aerie-pharmaceuticals-aeri-in-q1-earnings-cm779429,Aerie Pharmaceuticals Inc AERI is scheduled to report first quarter 2017 results on May 2 Last quarter the company missed expectations by 33 85 In fact Aerie s performance over the last four quarters has been disappointing The company reported a wider than expected loss in the
FGEN,FGEN:UW,BBG0077ZBFS3,"Akebia Surges but is Still Undervalued, Making Takeover a Potential Remedy",2017-04-26 14:59:00 +0000,http://finance.yahoo.com/r/166fa290-1f03-3b0f-ae42-5bfdc70ff18e/akebia-surges-but-is-still-undervalued-making-takeover-a-potential-remedy.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,Akebia is a lot like other small biotech companies with quality management teams executing well but ignored by investors for reasons that don't really make much sense fundamentally.
FGEN,FGEN:UW,BBG0077ZBFS3,What Awaits Aerie Pharmaceuticals (AERI) in Q1 Earnings?,2017-04-26 13:04:01 +0000,http://finance.yahoo.com/news/awaits-aerie-pharmaceuticals-aeri-q1-130401995.html?.tsrc=rss,"Aerie Pharmaceuticals, Inc. (AERI) is scheduled to report first-quarter 2017 results on May 2."
FGEN,FGEN:UW,BBG0077ZBFS3,"Akebia expands anemia drug pact with Japanese firm, lifting shares",2017-04-25 23:00:12 +0000,http://finance.yahoo.com/r/1d8d6300-df37-3b81-9dcb-000365088d8c/akebia-expands-anemia-drug-pact-with-japanese-firm.html?ana=yahoo&yptr=yahoo&.tsrc=rss,"Shares of Cambridge-based Akebia Therapeutics spiked on Tuesday after the company said it had expanded a potentially lucrative collaboration deal for its anemia drug.  The expanded agreement announced on Tuesday covers development and commercialization in Europe, China and other territories, with Akebia set to receive $208 million in committed funds and up to $657 million in milestone payments.  Vadadustat, a potential treatment for anemia associated with chronic kidney disease, is currently being tested in Phase 3 trials."
FGEN,FGEN:UW,BBG0077ZBFS3,"Akebia Expands Anemia Pill Partnership to Include Europe, China Rights",2017-04-25 20:25:00 +0000,http://finance.yahoo.com/r/d829939c-7f08-3dc9-a960-1a14a4d728f9/akebia-expands-anemia-pill-partnership-to-include-europe-china-rights.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,The new licensing deal between Akebia and Otsuka expands upon a pact made last December for U.S. commercial rights.
FGEN,FGEN:UW,BBG0077ZBFS3,"Commit To Buy FibroGen At $20, Earn 12.8% Annualized Using Options",2017-04-25 17:08:03 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/S13ZPIQMznA/commit-to-buy-fibrogen-at-20-earn-128-annualized-using-options-cm778843,Investors considering a purchase of FibroGen Inc Symbol FGEN shares but cautious about paying the going market price of 27 30 share might benefit from considering selling puts among the alternative strategies at their disposal One interesting put contract in particular is the September
FGEN,FGEN:UW,BBG0077ZBFS3,"Gainers & Losers Of Apr.6: HTGM, AKTX, FGEN, ARLZ, ADAP...",2017-04-06 22:19:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/q9SnlHJpUF4/gainers--losers-of-apr6-htgm-aktx-fgen-arlz-adap-20170406-01370,"Gainers & Losers Of Apr.6: HTGM, AKTX, FGEN, ARLZ, ADAP..."
FGEN,FGEN:UW,BBG0077ZBFS3,Why FibroGen Inc Popped Higher Today,2017-04-06 18:55:30 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Q8FCrc3uv1g/why-fibrogen-inc-popped-higher-today-cm770971,What happened FibroGen NASDAQ FGEN is up 15 5 at 12 17 p m EDT after announcing that it sold 5 228 750 shares at 22 95 per share to raise approximately 120 million So what Secondary offerings are a necessary evil for most development stage biotechs They raise
FGEN,FGEN:UW,BBG0077ZBFS3,Why FibroGen Inc Popped Higher Today,2017-04-06 16:59:00 +0000,http://finance.yahoo.com/r/bcf4148d-5a85-35ac-b3cb-d75d19baf574/why-fibrogen-inc-popped-higher-today.aspx?yptr=yahoo&.tsrc=rss,The biotech makes a stock offering at a good price.
FGEN,FGEN:UW,BBG0077ZBFS3,Traders Are Focused on the Big-Caps,2017-04-06 14:38:00 +0000,http://finance.yahoo.com/r/9e5645fc-3214-30e8-b51e-0f98e1c65d64/traders-are-focused-big-caps?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,The refusal to gap down at the open was probably a short-term negative.
FGEN,FGEN:UW,BBG0077ZBFS3,"FibroGen, Inc. Announces Pricing of Follow-On Offering of Common Stock",2017-04-06 11:00:00 +0000,http://finance.yahoo.com/news/fibrogen-inc-announces-pricing-offering-110000155.html?.tsrc=rss,"SAN FRANCISCO, April 06, 2017-- FibroGen, Inc., a science-based biopharmaceutical company, today announced that the company has priced an underwritten follow-on offering, which is expected to raise gross ..."
FGEN,FGEN:UW,BBG0077ZBFS3,"FibroGen, Inc. breached its 50 day moving average in a Bearish Manner : FGEN-US : April 4, 2017",2017-04-04 12:23:50 +0000,http://finance.yahoo.com/r/05648d5b-d782-3c36-adc9-1364d3802205/fibrogen-inc-breached-its-50-day-moving-average-in-a-bearish-manner-fgen-us-april-4-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceClick here to see latest analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for FibroGen, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average ... Read more
<b>(Read more...)</b>"
FGEN,FGEN:UW,BBG0077ZBFS3,7:07 am FibroGen announces that the China Food and Drug Administration has approved the Co's clinical trial application in China for a Phase 2/3 pivotal trial of roxadustat in anemia associated with lower risk myelodysplastic syndromes,2017-04-02 11:07:00 +0000,http://finance.yahoo.com/news/inplay-briefing-com-055139997.html#fgen,7:07 am FibroGen announces that the China Food and Drug Administration has approved the Co's clinical trial application in China for a Phase 2/3 pivotal trial of roxadustat in anemia associated with lower risk myelodysplastic syndromes
FGEN,FGEN:UW,BBG0077ZBFS3,"FIBROGEN INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits",2017-03-31 11:09:45 +0000,http://biz.yahoo.com/e/170331/fgen8-k.html,"FIBROGEN INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits"
FGEN,FGEN:UW,BBG0077ZBFS3,FibroGen Announces China FDA Approval of CTA to Conduct Pivotal Phase 2/3 Clinical Trial of Roxadustat in Anemia Associated With Lower Risk MDS,2017-03-31 11:05:00 +0000,http://finance.yahoo.com/news/fibrogen-announces-china-fda-approval-110500941.html,"[GlobeNewswire] - SAN FRANCISCO, March 31, 2017-- FibroGen, Inc., a science-based biopharmaceutical company, today announced the approval by the China Food and Drug Administration of the Company’ s clinical trial application ..."
FGEN,FGEN:UW,BBG0077ZBFS3,FibroGen Announces China FDA Approval of CTA to Conduct Pivotal Phase 2/3 Clinical Trial of Roxadustat in Anemia Associated With Lower Risk MDS,2017-03-31 11:05:00 +0000,http://finance.yahoo.com/news/fibrogen-announces-china-fda-approval-110500941.html?.tsrc=rss,"SAN FRANCISCO, March 31, 2017-- FibroGen, Inc., a science-based biopharmaceutical company, today announced the approval by the China Food and Drug Administration of the Company’ s clinical trial application ..."
FGEN,FGEN:UW,BBG0077ZBFS3,Positive Results Published in Nephrology Dialysis Transplantation From Two China Phase 2 Trials of Roxadustat for Treatment of Anemia in Chronic Kidney Disease,2017-03-30 11:00:00 +0000,http://finance.yahoo.com/news/positive-results-published-nephrology-dialysis-110000537.html,"[GlobeNewswire] - SAN FRANCISCO, March 30, 2017-- FibroGen, Inc., a science-based biopharmaceutical company, today announced that clinical results from two Phase 2 studies in China of roxadustat for the treatment of anemia ..."
FGEN,FGEN:UW,BBG0077ZBFS3,Positive Results Published in Nephrology Dialysis Transplantation From Two China Phase 2 Trials of Roxadustat for Treatment of Anemia in Chronic Kidney Disease,2017-03-30 11:00:00 +0000,http://finance.yahoo.com/news/positive-results-published-nephrology-dialysis-110000537.html?.tsrc=rss,"SAN FRANCISCO, March 30, 2017-- FibroGen, Inc., a science-based biopharmaceutical company, today announced that clinical results from two Phase 2 studies in China of roxadustat for the treatment of anemia ..."
FGEN,FGEN:UW,BBG0077ZBFS3,"FibroGen, Inc. breached its 50 day moving average in a Bullish Manner : FGEN-US : March 23, 2017",2017-03-23 12:05:45 +0000,http://www.capitalcube.com/blog/index.php/fibrogen-inc-breached-its-50-day-moving-average-in-a-bullish-manner-fgen-us-march-23-2017/,"FibroGen, Inc. breached its 50 day moving average in a Bullish Manner : FGEN-US : March 23, 2017"
FGEN,FGEN:UW,BBG0077ZBFS3,FIBROGEN INC Financials,2017-03-07 18:04:14 +0000,http://finance.yahoo.com/q/is?s=fgen,FIBROGEN INC Financials
FGEN,FGEN:UW,BBG0077ZBFS3,"FibroGen, Inc. :FGEN-US: Earnings Analysis: Q4, 2016 By the Numbers : March 7, 2017",2017-03-07 16:56:19 +0000,http://finance.yahoo.com/r/736398f4-6fce-3ff9-9f31-db17cf5bd219/fibrogen-inc-fgen-us-earnings-analysis-q4-2016-by-the-numbers-march-7-2017?yptr=yahoo&.tsrc=rss,"Categories:   Yahoo Finance Get free summary analysis FibroGen, Inc. reports financial results for the quarter ended December 31, 2016. We analyze the earnings along side the following peers of FibroGen, Inc. – Illumina, Inc., Acceleron Pharma Inc and Accelerate Diagnostics, Inc. (ILMN-US, XLRN-US and AXDX-US) that have also reported for this period. Highlights Summary numbers: Revenues of USD ... Read more    
<b>(Read more...)</b>"
FGEN,FGEN:UW,BBG0077ZBFS3,"FibroGen, Inc. :FGEN-US: Earnings Analysis: Q4, 2016 By the Numbers : March 7, 2017",2017-03-07 16:56:19 +0000,http://www.capitalcube.com/blog/index.php/fibrogen-inc-fgen-us-earnings-analysis-q4-2016-by-the-numbers-march-7-2017/,"FibroGen, Inc. :FGEN-US: Earnings Analysis: Q4, 2016 By the Numbers : March 7, 2017"
FGEN,FGEN:UW,BBG0077ZBFS3,"FIBROGEN INC Files SEC form 8-K, Entry into a Material Definitive Agreement",2017-03-02 21:40:11 +0000,http://biz.yahoo.com/e/170302/fgen8-k.html,"FIBROGEN INC Files SEC form 8-K, Entry into a Material Definitive Agreement"
FGEN,FGEN:UW,BBG0077ZBFS3,Edited Transcript of FGEN earnings conference call or presentation 1-Mar-17 9:30pm GMT,2017-03-02 20:04:23 +0000,http://finance.yahoo.com/news/edited-transcript-fgen-earnings-conference-200423681.html,Edited Transcript of FGEN earnings conference call or presentation 1-Mar-17 9:30pm GMT
FGEN,FGEN:UW,BBG0077ZBFS3,Edited Transcript of FGEN earnings conference call or presentation 1-Mar-17 9:30pm GMT,2017-03-02 20:04:23 +0000,http://finance.yahoo.com/news/edited-transcript-fgen-earnings-conference-200423681.html?.tsrc=rss,Q4 2016 FibroGen Inc Earnings Call
FGEN,FGEN:UW,BBG0077ZBFS3,FibroGen Inc Earnings Call scheduled for 4:30 pm ET today,2017-03-01 21:30:00 +0000,http://biz.yahoo.com/cc/0/155870.html,FibroGen Inc Earnings Call scheduled for 4:30 pm ET today
FGEN,FGEN:UW,BBG0077ZBFS3,"FIBROGEN INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits",2017-03-01 21:07:40 +0000,http://biz.yahoo.com/e/170301/fgen8-k.html,"FIBROGEN INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits"
FGEN,FGEN:UW,BBG0077ZBFS3,FibroGen Reports Fiscal 2016 Financial Results,2017-03-01 21:02:00 +0000,http://finance.yahoo.com/news/fibrogen-reports-fiscal-2016-financial-210200279.html,"[GlobeNewswire] - SAN FRANCISCO, March 01, 2017-- FibroGen, Inc., a science-based biopharmaceutical company, today reported financial results for the year ended December 31, 2016, and provided an update on the company’ ..."
FGEN,FGEN:UW,BBG0077ZBFS3,FibroGen Reports Fiscal 2016 Financial Results,2017-03-01 21:02:00 +0000,http://finance.yahoo.com/news/fibrogen-reports-fiscal-2016-financial-210200279.html?.tsrc=rss,"SAN FRANCISCO, March 01, 2017-- FibroGen, Inc., a science-based biopharmaceutical company, today reported financial results for the year ended December 31, 2016, and provided an update on the company’ ..."
FGEN,FGEN:UW,BBG0077ZBFS3,"After-Hours Earnings Report for March 1, 2017 :  AVGO, MNST, OPK, VGR, XON, FSIC, JUNO, ICUI, NKTR, SQM, FGEN, GKOS",2017-03-01 20:11:56 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ICffZYcD1Ho/after-hours-earnings-report-for-march-1-2017-avgo-mnst-opk-vgr-xon-fsic-juno-icui-nktr-sqm-fgen-gkos-cm754988,The following companies are expected to report earnings after hours on 03 01 2017 Visit our Earnings Calendar for a full list of expected earnings releases Broadcom Limited AVGO is reporting for the quarter ending January 31 2017 The electric
FGEN,FGEN:UW,BBG0077ZBFS3,Q4 2016 FibroGen Inc Earnings Release - After Market Close,2017-03-01 12:07:03 +0000,http://biz.yahoo.com/research/earncal/20170301.html?t=fgen,Q4 2016 FibroGen Inc Earnings Release - After Market Close
FGEN,FGEN:UW,BBG0077ZBFS3,"FibroGen to Report Fiscal 2016 Financial Results on March 1, 2017",2017-02-23 03:37:55 +0000,http://finance.yahoo.com/news/fibrogen-report-fiscal-2016-financial-033755581.html,"[GlobeNewswire] - SAN FRANCISCO, Feb. 22, 2017-- FibroGen, Inc., a science-based biopharmaceutical company, today announced that it will report financial results for the year ended December 31, 2016, on Wednesday, March ..."
FGEN,FGEN:UW,BBG0077ZBFS3,"FibroGen to Report Fiscal 2016 Financial Results on March 1, 2017",2017-02-23 03:37:55 +0000,http://finance.yahoo.com/news/fibrogen-report-fiscal-2016-financial-033755581.html?.tsrc=rss,"SAN FRANCISCO, Feb. 22, 2017-- FibroGen, Inc., a science-based biopharmaceutical company, today announced that it will report financial results for the year ended December 31, 2016, on Wednesday, March ..."
FGEN,FGEN:UW,BBG0077ZBFS3,"FIBROGEN INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits",2017-02-16 13:02:48 +0000,http://biz.yahoo.com/e/170216/fgen8-k.html,"FIBROGEN INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits"
FGEN,FGEN:UW,BBG0077ZBFS3,FibroGen Announces Publication of Pamrevlumab (FG-3019) Clinical Data in Pancreatic Cancer Showing Safety and Improved Survival Outcomes in Combination with Chemotherapy,2017-02-03 16:06:41 +0000,http://finance.yahoo.com/news/fibrogen-announces-publication-pamrevlumab-fg-160641416.html?.tsrc=rss,"SAN FRANCISCO, Feb. 03, 2017-- FibroGen, Inc.,, a science-based biopharmaceutical company, today announced that clinical results from the company’ s open-label, dose-escalation Phase 1/ 2 study of pamrevlumab ..."
FGEN,FGEN:UW,BBG0077ZBFS3,FibroGen Announces Publication of Pamrevlumab (FG-3019) Clinical Data in Pancreatic Cancer Showing Safety and Improved Survival Outcomes in Combination with Chemotherapy,2017-02-03 16:06:41 +0000,http://finance.yahoo.com/news/fibrogen-announces-publication-pamrevlumab-fg-160641416.html,"[GlobeNewswire] - SAN FRANCISCO, Feb. 03, 2017-- FibroGen, Inc.,, a science-based biopharmaceutical company, today announced that clinical results from the company’ s open-label, dose-escalation Phase 1/ 2 study of pamrevlumab ..."
FGEN,FGEN:UW,BBG0077ZBFS3,"FibroGen, Inc. breached its 50 day moving average in a Bearish Manner : FGEN-US : January 31, 2017",2017-01-31 14:32:46 +0000,http://finance.yahoo.com/r/61a03309-cebe-30a3-b151-e0e2d9e50298/fibrogen-inc-breached-its-50-day-moving-average-in-a-bearish-manner-fgen-us-january-31-2017?yptr=yahoo&.tsrc=rss,"Categories:   ETFs Yahoo Finance Click here to see latest analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for FibroGen, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average ... Read more    
<b>(Read more...)</b>"
FGEN,FGEN:UW,BBG0077ZBFS3,"FibroGen, Inc. breached its 50 day moving average in a Bearish Manner : FGEN-US : January 31, 2017",2017-01-31 14:32:46 +0000,http://www.capitalcube.com/blog/index.php/fibrogen-inc-breached-its-50-day-moving-average-in-a-bearish-manner-fgen-us-january-31-2017/,"FibroGen, Inc. breached its 50 day moving average in a Bearish Manner : FGEN-US : January 31, 2017"
FGEN,FGEN:UW,BBG0077ZBFS3,"AEZS Inches Closer To D-Day, EYEG Catches Investors' Eyes, MCRB On Watch",2017-01-31 03:00:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/gUAgYE_P7wI/aezs-inches-closer-to-dday-eyeg-catches-investors-eyes-mcrb-on-watch-20170131-00111,"AEZS Inches Closer To D-Day, EYEG Catches Investors' Eyes, MCRB On Watch"
FGEN,FGEN:UW,BBG0077ZBFS3,Aurinia Pharmaceuticals (AUPH) Jumps: Stock Rises 5.6%,2017-01-30 15:36:31 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/MIkLIwQWJ-8/aurinia-pharmaceuticals-auph-jumps-stock-rises-56-cm740100,Aurinia Pharmaceuticals Inc AUPH was a big mover last session as its shares rose almost 6 on the day The move came after the company announced that it has selected Worldwide Clinical Trials as its Clinical Research Organization for the AURORA Phase 3 study of volcosporin for the treatment
FGEN,FGEN:UW,BBG0077ZBFS3,"Premarket Biotech Movers: Ironwood Pharmaceuticals, Rigel Pharmaceuticals, FibroGen",2017-01-30 14:21:00 +0000,https://www.thestreet.com/story/13970890/1/premarket-biotech-movers-ironwood-pharmaceuticals-rigel-pharmaceuticals-fibrogen.html?puc=yahoo&cm_ven=YAHOO,"Premarket Biotech Movers: Ironwood Pharmaceuticals, Rigel Pharmaceuticals, FibroGen"
FGEN,FGEN:UW,BBG0077ZBFS3,"Premarket Biotech Movers: Ironwood Pharmaceuticals, Rigel Pharmaceuticals, FibroGen",2017-01-30 14:21:00 +0000,http://finance.yahoo.com/r/2d8f11c4-7079-3fb8-9177-c922a0c779fb/premarket-biotech-movers-ironwood-pharmaceuticals-rigel-pharmaceuticals-fibrogen.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,"Ironwood Pharmaceuticals, Rigel Pharmaceuticals and FibroGen were among the biotech stock movers in premarket trading on Monday."
FGEN,FGEN:UW,BBG0077ZBFS3,Aurinia Pharmaceuticals (AUPH) Jumps: Stock Rises 5.6%,2017-01-30 13:25:01 +0000,http://finance.yahoo.com/news/aurinia-pharmaceuticals-auph-jumps-stock-132501025.html,Aurinia Pharmaceuticals (AUPH) Jumps: Stock Rises 5.6%
FGEN,FGEN:UW,BBG0077ZBFS3,Aurinia Pharmaceuticals (AUPH) Jumps: Stock Rises 5.6%,2017-01-30 13:25:01 +0000,http://finance.yahoo.com/news/aurinia-pharmaceuticals-auph-jumps-stock-132501025.html?.tsrc=rss,"Aurinia Pharmaceuticals Inc. (AUPH) moved big last session, as its shares jumped almost 6% on the day."
FGEN,FGEN:UW,BBG0077ZBFS3,"FIBROGEN INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits",2017-01-30 12:07:33 +0000,http://biz.yahoo.com/e/170130/fgen8-k.html,"FIBROGEN INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits"
FGEN,FGEN:UW,BBG0077ZBFS3,FibroGen’s Roxadustat (FG-4592) Meets Primary Endpoints in Two Phase 3 Anemia Studies in China,2017-01-30 12:00:00 +0000,http://finance.yahoo.com/news/fibrogen-roxadustat-fg-4592-meets-120000721.html,"[GlobeNewswire] - SAN FRANCISCO, Jan. 30, 2017-- FibroGen, Inc., a science-based biopharmaceutical company, and its subsidiary FibroGen China Medical Technology Development Co., Ltd., today reported positive topline results ..."
FGEN,FGEN:UW,BBG0077ZBFS3,FibroGen’s Roxadustat (FG-4592) Meets Primary Endpoints in Two Phase 3 Anemia Studies in China,2017-01-30 12:00:00 +0000,http://finance.yahoo.com/news/fibrogen-roxadustat-fg-4592-meets-120000721.html?.tsrc=rss,"SAN FRANCISCO, Jan. 30, 2017-- FibroGen, Inc., a science-based biopharmaceutical company, and its subsidiary FibroGen China Medical Technology Development Co., Ltd., today reported positive topline results ..."
FGEN,FGEN:UW,BBG0077ZBFS3,FibroGen's Roxadustat Meets Primary Goals In Two Phase 3 Anemia Studies In China,2017-01-30 07:14:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/qjafEsKRp4Y/fibrogens-roxadustat-meets-primary-goals-in-two-phase-3-anemia-studies-in-china-20170130-00290,FibroGen's Roxadustat Meets Primary Goals In Two Phase 3 Anemia Studies In China
FGEN,FGEN:UW,BBG0077ZBFS3,"FibroGen (FGEN) Shares March Higher, Can It Continue?",2017-01-23 14:44:35 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/uzhMjWb5yHE/fibrogen-fgen-shares-march-higher-can-it-continue-cm736662,FibroGen Inc FGEN has been on the move lately as the stock has risen by 29 3 in the past four weeks and it is currently trading well above its 20 Day SMA This is a pretty solid move higher but the question that has to be on investors minds right now is can this trend continue
FGEN,FGEN:UW,BBG0077ZBFS3,"FibroGen (FGEN) Shares March Higher, Can It Continue?",2017-01-23 13:01:01 +0000,http://finance.yahoo.com/news/fibrogen-fgen-shares-march-higher-130101409.html?.tsrc=rss,"FibroGen, Inc. (FGEN) has been on the move lately as the stock has risen by 29.3% in the past four weeks, and it is currently trading well above its 20-Day SMA"
FGEN,FGEN:UW,BBG0077ZBFS3,"FibroGen (FGEN) Shares March Higher, Can It Continue?",2017-01-23 13:01:01 +0000,http://finance.yahoo.com/news/fibrogen-fgen-shares-march-higher-130101409.html,"FibroGen (FGEN) Shares March Higher, Can It Continue?"
FGEN,FGEN:UW,BBG0077ZBFS3,Pamrevlumab Pancreatic Cancer Clinical Data Presented at ASCO 2017 Gastrointestinal Cancers Symposium,2017-01-20 22:06:22 +0000,http://finance.yahoo.com/news/pamrevlumab-pancreatic-cancer-clinical-data-220622088.html,"[GlobeNewswire] - SAN FRANCISCO, Jan. 20, 2017-- FibroGen, Inc. today announced that updated results from an ongoing clinical study of pamrevlumab in combination with standard-of-care chemotherapy in patients with locally ..."
FGEN,FGEN:UW,BBG0077ZBFS3,Pamrevlumab Pancreatic Cancer Clinical Data Presented at ASCO 2017 Gastrointestinal Cancers Symposium,2017-01-20 22:06:22 +0000,http://finance.yahoo.com/news/pamrevlumab-pancreatic-cancer-clinical-data-220622088.html?.tsrc=rss,"SAN FRANCISCO, Jan. 20, 2017-- FibroGen, Inc. today announced that updated results from an ongoing clinical study of pamrevlumab in combination with standard-of-care chemotherapy in patients with locally ..."
FGEN,FGEN:UW,BBG0077ZBFS3,Here Are Two Market Moving Biotech Catalysts To Watch This Week,2017-01-17 14:40:44 +0000,http://finance.yahoo.com/r/984a25cf-9089-3844-abae-79f17bf33b8a/here-are-two-market-moving-biotech-catalysts-to-watch-this-week-519026?yptr=yahoo&.tsrc=rss,"The biotechnology sector is in full swing for the New Year, and while the JP Morgan conference is now in the rearview mirror, there are still plenty of potential catalysts set to hit press between now and the end of January. Here are two of the releases that we are most highly anticipating, with a […]"
FGEN,FGEN:UW,BBG0077ZBFS3,Here Are Two Market Moving Biotech Catalysts To Watch This Week,2017-01-17 14:40:44 +0000,http://www.insidermonkey.com/blog/here-are-two-market-moving-biotech-catalysts-to-watch-this-week-519026/,Here Are Two Market Moving Biotech Catalysts To Watch This Week
FGEN,FGEN:UW,BBG0077ZBFS3,6 Major FDA Decisions and Biopharma Catalysts Coming in January and February,2017-01-06 15:25:51 +0000,http://finance.yahoo.com/news/6-major-fda-decisions-biopharma-152551867.html,6 Major FDA Decisions and Biopharma Catalysts Coming in January and February
FGEN,FGEN:UW,BBG0077ZBFS3,6 Major FDA Decisions and Biopharma Catalysts Coming in January and February,2017-01-06 15:25:51 +0000,http://finance.yahoo.com/news/6-major-fda-decisions-biopharma-152551867.html?.tsrc=rss,Some biopharma companies can see a massive upside just from winning a single mid-stage trial or even achieving as much as a Fast Track designation from the FDA.
FGEN,FGEN:UW,BBG0077ZBFS3,"Better Buy: Organovo Holdings, Inc. vs. Akebia Therapeutics, Inc.",2017-01-05 17:56:19 +0000,http://www.fool.com/investing/2017/01/05/better-buy-organovo-holdings-inc-vs-akebia-therape.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,"Better Buy: Organovo Holdings, Inc. vs. Akebia Therapeutics, Inc."
FGEN,FGEN:UW,BBG0077ZBFS3,"Better Buy: Organovo Holdings, Inc. vs. Akebia Therapeutics, Inc.",2017-01-05 17:56:19 +0000,http://finance.yahoo.com/r/242023b6-8504-3733-a46b-3aa410f11724/better-buy-organovo-holdings-inc-vs-akebia-therape.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2&yptr=yahoo&.tsrc=rss,Which stock wins in a head-to-head match-up between Organovo and Akebia Therapeutics?
FGEN,FGEN:UW,BBG0077ZBFS3,"Better Buy: Organovo Holdings, Inc. vs. Akebia Therapeutics, Inc.",2017-01-05 17:40:36 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/c8FaNKum5YU/better-buy-organovo-holdings-inc-vs-akebia-therapeutics-inc-cm729946,At first glance Organovo Holdings NASDAQ ONVO versus Akebia Therapeutics NASDAQ AKBA might seem like an apples and oranges comparison Organovo develops 3D bioprinted human tissues while Akebia has a promising anemia drug in its pipeline There are similarities though
FGEN,FGEN:UW,BBG0077ZBFS3,Will 2017 Be a Make or Break Year for FibroGen?,2016-12-30 15:45:08 +0000,http://finance.yahoo.com/news/2017-break-fibrogen-154508853.html,Will 2017 Be a Make or Break Year for FibroGen?
FGEN,FGEN:UW,BBG0077ZBFS3,"FibroGen, Inc. – Value Analysis (NASDAQ:FGEN) : December 23, 2016",2016-12-23 14:26:35 +0000,http://www.capitalcube.com/blog/index.php/fibrogen-inc-value-analysis-nasdaqfgen-december-23-2016/,"FibroGen, Inc. – Value Analysis (NASDAQ:FGEN) : December 23, 2016"
FGEN,FGEN:UW,BBG0077ZBFS3,"Commit To Purchase FibroGen At $10, Earn 10.2% Annualized Using Options",2016-12-22 17:58:39 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/NPj9-Ndvi70/commit-to-purchase-fibrogen-at-10-earn-102-annualized-using-options-cm725227,Investors considering a purchase of FibroGen Inc Symbol FGEN shares but cautious about paying the going market price of 19 80 share might benefit from considering selling puts among the alternative strategies at their disposal One interesting put contract in particular is the December
FGEN,FGEN:UW,BBG0077ZBFS3,"FibroGen, Inc. breached its 50 day moving average in a Bearish Manner : FGEN-US : December 22, 2016",2016-12-22 12:26:44 +0000,http://www.capitalcube.com/blog/index.php/fibrogen-inc-breached-its-50-day-moving-average-in-a-bearish-manner-fgen-us-december-22-2016/,"FibroGen, Inc. breached its 50 day moving average in a Bearish Manner : FGEN-US : December 22, 2016"
FGEN,FGEN:UW,BBG0077ZBFS3,Why Akebia Therapeutics Inc Stock Zoomed Higher Today,2016-12-20 20:58:09 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Wf8VpmE4nUM/why-akebia-therapeutics-inc-stock-zoomed-higher-today-cm724250,Image source Getty Images What happened Akebia Therapeutics NASDAQ AKBA 160 stock is up 24 at 2 10 p m EST after signing a deal with Japanese drugmaker Otsuka Pharmaceutical to develop and sell vadadustat Akebia s oral hypoxia inducible factor prolyl hydroxylase HIF
FGEN,FGEN:UW,BBG0077ZBFS3,Why Akebia Therapeutics Inc Stock Zoomed Higher Today,2016-12-20 19:19:29 +0000,http://www.fool.com/investing/2016/12/20/why-akebia-therapeutics-inc-zoomed-higher-today.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Why Akebia Therapeutics Inc Stock Zoomed Higher Today
FGEN,FGEN:UW,BBG0077ZBFS3,Akebia Funds Late-Stage Studies of Anemia Pill With Partnership for U.S. Commercial Rights,2016-12-20 12:01:00 +0000,https://www.thestreet.com/story/13932037/1/akebia-funds-late-stage-studies-of-anemia-pill-with-partnership-for-u-s-commercial-rights.html?puc=yahoo&cm_ven=YAHOO,Akebia Funds Late-Stage Studies of Anemia Pill With Partnership for U.S. Commercial Rights
FGEN,FGEN:UW,BBG0077ZBFS3,"ETFs with exposure to FibroGen, Inc. : December 16, 2016",2016-12-16 18:40:59 +0000,http://www.capitalcube.com/blog/index.php/etfs-with-exposure-to-fibrogen-inc-december-16-2016/,"ETFs with exposure to FibroGen, Inc. : December 16, 2016"
FGEN,FGEN:UW,BBG0077ZBFS3,Is FibroGen Inc (FGEN) a Good Stock to Buy?,2016-12-10 20:47:58 +0000,http://www.insidermonkey.com/blog/is-fibrogen-inc-fgen-a-good-stock-to-buy-502180/,Is FibroGen Inc (FGEN) a Good Stock to Buy?
FGEN,FGEN:UW,BBG0077ZBFS3,GSK chases Astra with start of big anaemia drug trials,2016-11-24 12:13:59 +0000,http://finance.yahoo.com/news/gsk-chases-astra-start-big-121359335.html,"[Reuters] - GlaxoSmithKline has started pivotal trials of an experimental anaemia drug, chasing AstraZeneca in the race to develop a medicine that mimics the body's response to high altitude. GSK's daprodustat, given as a pill, is designed to displace injectable EPO products that are used widely in patients with chronic kidney disease. GSK said on Thursday its two Phase III clinical studies would enrol a combined total of 7,500 patients with kidney disease."
FGEN,FGEN:UW,BBG0077ZBFS3,"ETFs with exposure to FibroGen, Inc. : November 18, 2016",2016-11-18 18:08:54 +0000,http://www.capitalcube.com/blog/index.php/etfs-with-exposure-to-fibrogen-inc-november-18-2016/,"ETFs with exposure to FibroGen, Inc. : November 18, 2016"
FGEN,FGEN:UW,BBG0077ZBFS3,"FibroGen, Inc. :FGEN-US: Earnings Analysis: Q3, 2016 By the Numbers : November 16, 2016",2016-11-16 16:04:34 +0000,http://www.capitalcube.com/blog/index.php/fibrogen-inc-fgen-us-earnings-analysis-q3-2016-by-the-numbers-november-16-2016/,"FibroGen, Inc. :FGEN-US: Earnings Analysis: Q3, 2016 By the Numbers : November 16, 2016"
FGEN,FGEN:UW,BBG0077ZBFS3,"FIBROGEN INC Files SEC form 8-K, Change in Directors or Principal Officers",2016-11-15 22:19:02 +0000,http://biz.yahoo.com/e/161115/fgen8-k.html,"FIBROGEN INC Files SEC form 8-K, Change in Directors or Principal Officers"
FGEN,FGEN:UW,BBG0077ZBFS3,"FibroGen, Inc. breached its 50 day moving average in a Bullish Manner : FGEN-US : November 11, 2016",2016-11-11 12:08:52 +0000,http://www.capitalcube.com/blog/index.php/fibrogen-inc-breached-its-50-day-moving-average-in-a-bullish-manner-fgen-us-november-11-2016/,"FibroGen, Inc. breached its 50 day moving average in a Bullish Manner : FGEN-US : November 11, 2016"
FGEN,FGEN:UW,BBG0077ZBFS3,Edited Transcript of FGEN earnings conference call or presentation 8-Nov-16 9:30pm GMT,2016-11-09 19:23:53 +0000,http://finance.yahoo.com/news/edited-transcript-fgen-earnings-conference-192353998.html,Edited Transcript of FGEN earnings conference call or presentation 8-Nov-16 9:30pm GMT
FGEN,FGEN:UW,BBG0077ZBFS3,"Health Care Sector Update for 11/09/2016: FGEN,SCMP,CYH",2016-11-09 18:13:03 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/PT4NyAl-J78/health-care-sector-update-for-11092016-fgenscmpcyh-cm706621,Top Health Care StocksTop Health Care Stocks JNJ 2 72 JNJ 2 72 PFE 7 57 PFE 7 57 MRK 0 13 MRK 0 13 ABT 6 91 ABT 6 91 AMGN 6 27 AMGN 6 27 Health care stocks were extending their recent recovery with the NYSE Health Care Index advancing 2 2 while shares of health care companies
FGEN,FGEN:UW,BBG0077ZBFS3,FibroGen Inc Earnings Call scheduled for 4:30 pm ET today,2016-11-08 21:30:00 +0000,http://biz.yahoo.com/cc/9/154709.html,FibroGen Inc Earnings Call scheduled for 4:30 pm ET today
FGEN,FGEN:UW,BBG0077ZBFS3,FibroGen Reports Financial Results for the Third Quarter of 2016 and Provides Corporate Update,2016-11-08 21:09:09 +0000,http://www.publicnow.com/view/CDAC50CCBBEE412C62241B026476C08A759A17B2,"[at noodls] - -Completes Enrollment of Roxadustat Phase 3 Studies in China for Anemia in CKD - -Conference Call and Webcast to be Held Today at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time - SAN FRANCISCO, Nov. 08, ..."
FGEN,FGEN:UW,BBG0077ZBFS3,"FIBROGEN INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits",2016-11-08 21:06:59 +0000,http://biz.yahoo.com/e/161108/fgen8-k.html,"FIBROGEN INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits"
FGEN,FGEN:UW,BBG0077ZBFS3,Q3 2016 FibroGen Inc Earnings Release - After Market Close,2016-11-08 12:07:08 +0000,http://biz.yahoo.com/research/earncal/20161108.html?t=fgen,Q3 2016 FibroGen Inc Earnings Release - After Market Close
FGEN,FGEN:UW,BBG0077ZBFS3,This Healthcare Fund Just Had A Huge Q3: Here’s How,2016-11-03 20:59:00 +0000,http://www.insidermonkey.com/blog/this-healthcare-fund-just-had-a-huge-q3-heres-how-484834/,This Healthcare Fund Just Had A Huge Q3: Here’s How
FGEN,FGEN:UW,BBG0077ZBFS3,FibroGen Becomes Oversold (FGEN),2016-11-02 22:06:47 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/gnuT92Tr_rs/fibrogen-becomes-oversold-fgen-cm702848,Legendary investor Warren Buffett advises to be fearful when others are greedy and be greedy when others are fearful One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index or RSI which measures momentum on
FGEN,FGEN:UW,BBG0077ZBFS3,"FibroGen to Report Third Quarter 2016 Financial Results on November 8, 2016",2016-11-01 21:10:16 +0000,http://www.publicnow.com/view/E470929A9B2FC8B459B2893EDE220433828E1D5F,"[at noodls] - SAN FRANCISCO, Nov. 01, 2016 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), a research-based biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics ..."
FGEN,FGEN:UW,BBG0077ZBFS3,"ARIA To Face FDA In April, OPXA''s Woes Continue, Keep An Eye On OPHT",2016-11-01 01:49:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/KtfqL-CRm-k/aria-to-face-fda-in-april-opxas-woes-continue-keep-an-eye-on-opht-20161101-01238,"ARIA To Face FDA In April, OPXA''s Woes Continue, Keep An Eye On OPHT"
FGEN,FGEN:UW,BBG0077ZBFS3,FibroGen Completes Enrollment in Roxadustat Phase 3 Studies in China,2016-10-31 12:13:08 +0000,http://www.publicnow.com/view/3342F4669630E7006E4203769E961C15A6D50A8E,"[at noodls] - SAN FRANCISCO, Oct. 31, 2016 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), a research-based biopharmaceutical company, today reported completion of enrollment in its Phase 3 clinical trials in China ..."
FGEN,FGEN:UW,BBG0077ZBFS3,"ETF’s with exposure to FibroGen, Inc. : October 14, 2016",2016-10-14 14:44:06 +0000,http://www.capitalcube.com/blog/index.php/etfs-with-exposure-to-fibrogen-inc-october-14-2016/,"ETF’s with exposure to FibroGen, Inc. : October 14, 2016"
FGEN,FGEN:UW,BBG0077ZBFS3,"FibroGen, Inc. breached its 50 day moving average in a Bearish Manner : FGEN-US : October 13, 2016",2016-10-13 12:25:19 +0000,http://www.capitalcube.com/blog/index.php/fibrogen-inc-breached-its-50-day-moving-average-in-a-bearish-manner-fgen-us-october-13-2016/,"FibroGen, Inc. breached its 50 day moving average in a Bearish Manner : FGEN-US : October 13, 2016"
FGEN,FGEN:UW,BBG0077ZBFS3,"ETF’s with exposure to FibroGen, Inc. : September 28, 2016",2016-09-28 13:46:39 +0000,http://www.capitalcube.com/blog/index.php/etfs-with-exposure-to-fibrogen-inc-september-28-2016/,"ETF’s with exposure to FibroGen, Inc. : September 28, 2016"
FGEN,FGEN:UW,BBG0077ZBFS3,"FibroGen, Inc. breached its 50 day moving average in a Bullish Manner : FGEN-US : September 7, 2016",2016-09-07 12:07:05 +0000,http://www.capitalcube.com/blog/index.php/fibrogen-inc-breached-its-50-day-moving-average-in-a-bullish-manner-fgen-us-september-7-2016/,"FibroGen, Inc. breached its 50 day moving average in a Bullish Manner : FGEN-US : September 7, 2016"
FGEN,FGEN:UW,BBG0077ZBFS3,"FibroGen, Inc. breached its 50 day moving average in a Bearish Manner : FGEN-US : August 26, 2016",2016-08-26 12:10:44 +0000,http://www.capitalcube.com/blog/index.php/fibrogen-inc-breached-its-50-day-moving-average-in-a-bearish-manner-fgen-us-august-26-2016/,"FibroGen, Inc. breached its 50 day moving average in a Bearish Manner : FGEN-US : August 26, 2016"
FGEN,FGEN:UW,BBG0077ZBFS3,"ETF’s with exposure to FibroGen, Inc. : August 23, 2016",2016-08-23 15:50:11 +0000,http://www.capitalcube.com/blog/index.php/etfs-with-exposure-to-fibrogen-inc-august-23-2016/,"ETF’s with exposure to FibroGen, Inc. : August 23, 2016"
FGEN,FGEN:UW,BBG0077ZBFS3,"FibroGen, Inc. :FGEN-US: Earnings Analysis: Q2, 2016 By the Numbers : August 12, 2016",2016-08-12 14:34:46 +0000,http://www.capitalcube.com/blog/index.php/fibrogen-inc-fgen-us-earnings-analysis-q2-2016-by-the-numbers-august-12-2016/,"FibroGen, Inc. :FGEN-US: Earnings Analysis: Q2, 2016 By the Numbers : August 12, 2016"
FGEN,FGEN:UW,BBG0077ZBFS3,Edited Transcript of FGEN earnings conference call or presentation 8-Aug-16 8:30pm GMT,2016-08-09 17:05:53 +0000,http://finance.yahoo.com/news/edited-transcript-fgen-earnings-conference-170553005.html,Edited Transcript of FGEN earnings conference call or presentation 8-Aug-16 8:30pm GMT
FGEN,FGEN:UW,BBG0077ZBFS3,FibroGen Inc Earnings Call scheduled for 4:30 pm ET today,2016-08-08 20:30:00 +0000,http://biz.yahoo.com/cc/1/153461.html,FibroGen Inc Earnings Call scheduled for 4:30 pm ET today
FGEN,FGEN:UW,BBG0077ZBFS3,"FIBROGEN INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits",2016-08-08 20:07:02 +0000,http://biz.yahoo.com/e/160808/fgen8-k.html,"FIBROGEN INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits"
FGEN,FGEN:UW,BBG0077ZBFS3,FibroGen Reports Financial Results for the Second Quarter of 2016,2016-08-08 20:02:00 +0000,http://finance.yahoo.com/news/fibrogen-reports-financial-results-second-200200494.html,"[GlobeNewswire] - Enrollment Completed in Placebo-Controlled Study of FG-3019 in IPF China Phase 3 Top Line Data Expected by Year-End 2016. –Webcast Conference Call Scheduled for 4:30pm EDT Today–. SAN FRANCISCO, Aug. 08, ..."
FGEN,FGEN:UW,BBG0077ZBFS3,Q2 2016 FibroGen Inc Earnings Release - After Market Close,2016-08-08 11:07:03 +0000,http://biz.yahoo.com/research/earncal/20160808.html?t=fgen,Q2 2016 FibroGen Inc Earnings Release - After Market Close
FGEN,FGEN:UW,BBG0077ZBFS3,"FibroGen to Report Second Quarter 2016 Financial Results on August 8, 2016",2016-08-03 00:32:05 +0000,http://www.publicnow.com/view/A4EC478BE9DE81A6D881E54D286DD19CEC2B020F,"[at noodls] - SAN FRANCISCO, Aug. 02, 2016 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), a research-based biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics ..."
FGEN,FGEN:UW,BBG0077ZBFS3,"FIBROGEN INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits",2016-07-26 10:09:28 +0000,http://biz.yahoo.com/e/160726/fgen8-k.html,"FIBROGEN INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits"
FGEN,FGEN:UW,BBG0077ZBFS3,Astellas and FibroGen Announce First Patient Treated in Phase 3 Studies and Positive Phase 2 Results of Roxadustat in Patients with Chronic Kidney Disease in Japan,2016-07-26 01:28:04 +0000,http://www.publicnow.com/view/EA2680E82DA3D78299437AFE680320CCB40A6D9C,"[at noodls] - TOKYO and SAN FRANCISCO, July 25, 2016 (GLOBE NEWSWIRE) -- Astellas Pharma Inc. (TSE:4503) ('Astellas') and FibroGen, Inc. (Nasdaq:FGEN) ('FibroGen'), today announced the dosing of the first patient in ..."
FGEN,FGEN:UW,BBG0077ZBFS3,"FibroGen, Inc. breached its 50 day moving average in a Bullish Manner : FGEN-US : July 21, 2016",2016-07-21 12:08:06 +0000,http://www.capitalcube.com/blog/index.php/fibrogen-inc-breached-its-50-day-moving-average-in-a-bullish-manner-fgen-us-july-21-2016/,"FibroGen, Inc. breached its 50 day moving average in a Bullish Manner : FGEN-US : July 21, 2016"
FGEN,FGEN:UW,BBG0077ZBFS3,"FibroGen, Inc. – Value Analysis (NASDAQ:FGEN) : July 18, 2016",2016-07-18 19:45:24 +0000,http://www.capitalcube.com/blog/index.php/fibrogen-inc-value-analysis-nasdaqfgen-july-18-2016/,"FibroGen, Inc. – Value Analysis (NASDAQ:FGEN) : July 18, 2016"
FGEN,FGEN:UW,BBG0077ZBFS3,"FibroGen, Inc. breached its 50 day moving average in a Bullish Manner : FGEN-US : July 11, 2016",2016-07-11 12:07:26 +0000,http://www.capitalcube.com/blog/index.php/fibrogen-inc-breached-its-50-day-moving-average-in-a-bullish-manner-fgen-us-july-11-2016/,"FibroGen, Inc. breached its 50 day moving average in a Bullish Manner : FGEN-US : July 11, 2016"
FGEN,FGEN:UW,BBG0077ZBFS3,FibroGen Announces Receipt of $62 Million License Payment from AstraZeneca,2016-07-08 08:11:03 +0000,http://www.publicnow.com/view/FEA0F0DBCE7D255F94725962EA3081AA08A15661,"[at noodls] - SAN FRANCISCO, July 08, 2016 (GLOBE NEWSWIRE) -- FibroGen, Inc. (Nasdaq:FGEN) ('FibroGen'), a research-based biopharmaceutical company, announced today that it has received a scheduled $62 million license ..."
FGEN,FGEN:UW,BBG0077ZBFS3,"FIBROGEN INC Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a Vote of Securi",2016-06-10 21:30:02 +0000,http://biz.yahoo.com/e/160610/fgen8-k.html,"FIBROGEN INC Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a Vote of Securi"
FGEN,FGEN:UW,BBG0077ZBFS3,FibroGen Announces Initiation by Astellas of Phase 3 Clinical Study in Japan of Roxadustat/ASP1517 for the Treatment of Anemia of Chronic Kidney Disease Triggering $10.0 Million Milestone Payment,2016-06-09 11:19:03 +0000,http://www.publicnow.com/view/41579891A62A21CC453613A325ED9DA330310631,"[at noodls] - SAN FRANCISCO, June 09, 2016 (GLOBE NEWSWIRE) -- FibroGen, Inc. (Nasdaq:FGEN) ('FibroGen'), announced today that it will receive a $10.0 million milestone payment from Astellas Pharma Inc. (Astellas). ..."
FGEN,FGEN:UW,BBG0077ZBFS3,FibroGen to Present at the Goldman Sachs 37th Annual Global Healthcare Conference,2016-06-06 11:08:05 +0000,http://www.publicnow.com/view/295CCC7E2CEBAAC0115FA0C6C27D7AB3D2117DB0,"[at noodls] - SAN FRANCISCO, June 06, 2016 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), announced that Chief Executive Officer, Thomas B. Neff, will be presenting at the Goldman Sachs 37th Annual Global Healthcare ..."
FGEN,FGEN:UW,BBG0077ZBFS3,"FibroGen, Inc. breached its 50 day moving average in a Bullish Manner : FGEN-US : June 3, 2016",2016-06-03 12:07:39 +0000,http://www.capitalcube.com/blog/index.php/fibrogen-inc-breached-its-50-day-moving-average-in-a-bullish-manner-fgen-us-june-3-2016/,"FibroGen, Inc. breached its 50 day moving average in a Bullish Manner : FGEN-US : June 3, 2016"
FGEN,FGEN:UW,BBG0077ZBFS3,"Chairman’s Message during the FPH meeting on May 23, 2016",2016-05-29 18:00:08 +0000,http://www.publicnow.com/view/D67694D1C56DA503260359D38838AD914B6C4BB5,"[at noodls] - May 29, 2016 Six years ago we decided to express in a few words the vision of First Philippine Holdings Corp., which is to: 'Uplift lives through key industries and infrastructure that advance national ..."
FGEN,FGEN:UW,BBG0077ZBFS3,"ETF’s with exposure to FibroGen, Inc. : May 19, 2016",2016-05-19 23:24:39 +0000,http://www.capitalcube.com/blog/index.php/etfs-with-exposure-to-fibrogen-inc-may-19-2016/,"ETF’s with exposure to FibroGen, Inc. : May 19, 2016"
FGEN,FGEN:UW,BBG0077ZBFS3,"FibroGen, Inc. :FGEN-US: Earnings Analysis: Q1, 2016 By the Numbers",2016-05-17 18:45:11 +0000,http://www.capitalcube.com/blog/index.php/fibrogen-inc-fgen-us-earnings-analysis-q1-2016-by-the-numbers/,"FibroGen, Inc. :FGEN-US: Earnings Analysis: Q1, 2016 By the Numbers"
FGEN,FGEN:UW,BBG0077ZBFS3,Edited Transcript of FGEN earnings conference call or presentation 9-May-16 8:30pm GMT,2016-05-10 16:09:33 +0000,http://finance.yahoo.com/news/edited-transcript-fgen-earnings-conference-160933209.html,Edited Transcript of FGEN earnings conference call or presentation 9-May-16 8:30pm GMT
FGEN,FGEN:UW,BBG0077ZBFS3,FibroGen Reports Financial Results for the First Quarter of 2016,2016-05-09 20:18:18 +0000,http://www.publicnow.com/view/5744C1C0A8E3520BF2D88297CBC9729D4B4E8385,"[at noodls] - Continued Progress in Roxadustat Phase 3 Studies; Promising Interim Pancreatic Cancer Data -Webcast Conference Call Scheduled for 4:30pm EST Today- SAN FRANCISCO, May 09, 2016 (GLOBE NEWSWIRE) -- FibroGen, ..."
FGEN,FGEN:UW,BBG0077ZBFS3,"FibroGen to Report First Quarter 2016 Financial Results on May 9, 2016",2016-05-02 20:30:14 +0000,http://www.publicnow.com/view/89130B9612F5A6781D7C163E3CA745F0CCA17DF9,"[at noodls] - SAN FRANCISCO, May 02, 2016 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), a research-based biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics ..."
FGEN,FGEN:UW,BBG0077ZBFS3,Promising Phase 2 Data Show Roxadustat Corrected Anemia in Chronic Kidney Disease Patients Before Intervention with Dialysis,2016-04-21 03:22:33 +0000,http://www.publicnow.com/view/C74D5B25D09CAF05D777E5D3C76EFFA24AAED520,"[at noodls] - SAN FRANCISCO, April 20, 2016 (GLOBE NEWSWIRE) -- FibroGen, Inc. (Nasdaq:FGEN) ('FibroGen'), a research-based biopharmaceutical company, today announced that the Clinical Journal of the American Society ..."
FGEN,FGEN:UW,BBG0077ZBFS3,We Did The Math JKK Can Go To $150,2016-04-19 13:58:58 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/sYp9wgEK4So/we-did-the-math-jkk-can-go-to-150-cm608105,"Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel , we have compared the trading price of each holding against the average analyst 12 month forward target price, and computed the weighted average"
FGEN,FGEN:UW,BBG0077ZBFS3,FibroGen (FGEN) Shows Strength: Stock Moves Up 14%,2016-02-12 15:55:12 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Dk_EHX-YcHQ/fibrogen-fgen-shows-strength-stock-moves-up-14-cm579231,"FibroGen, Inc.FGEN was a big mover last session, as the company saw its shares rise roughly 14% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. Meanwhile,"
FGEN,FGEN:UW,BBG0077ZBFS3,"FibroGen Announces Early Phase 2 Data From a Clinical Study of FG-3019 in Combination With Chemotherapy as Neoadjuvant in Locally Advanced, Unresectable Pancreatic Cancer",2016-01-28 02:44:34 +0000,http://www.publicnow.com/view/3C0DCD445FC122B9791E54EC77CE4DB08C4685FA,"[at noodls] - , (GLOBE NEWSWIRE) -- () today announced early results from a Phase 2, randomized, open-label study of FG-3019, an investigational anti-fibrotic antibody, in combination with gemcitabine and nab-paclitaxel ..."
FGEN,FGEN:UW,BBG0077ZBFS3,"Commit To Purchase FibroGen At $12.50, Earn 15% Annualized Using Options",2016-01-27 18:21:20 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/QuKSnYmKvIQ/commit-to-purchase-fibrogen-at-1250-earn-15-annualized-using-options-cm571068,"Investors eyeing a purchase of FibroGen Inc (Symbol FGEN) shares, but cautious about paying the going market price of $19.71 share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in"
FGEN,FGEN:UW,BBG0077ZBFS3,FibroGen is Now Oversold (FGEN),2016-01-12 23:11:40 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/nisOgCpg-iE/fibrogen-is-now-oversold-fgen-cm564979,"Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis"
FGEN,FGEN:UW,BBG0077ZBFS3,3 Biotech Stocks to Buy in January,2016-01-12 13:15:04 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/cYxuoiVMTkA/3-biotech-stocks-to-buy-in-january-cm564355,Image source  TBIT via Pixabay.  Biotech stocks are off to a rough start in 2016. Several of the most popular exchange traded funds that focus on the industry have been sold
FGEN,FGEN:UW,BBG0077ZBFS3,Strength Seen in FibroGen (FGEN): Stock Rises 6.3%,2015-11-18 15:04:34 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/oxgW0T-f_uc/strength-seen-in-fibrogen-fgen-stock-rises-63-cm544402,"FibroGen, Inc.FGEN was a big mover last session with its shares rising over 6% on the day. The move came on solid volume with far more shares changing hands than in a normal session. This breaks the recent trend"
FGEN,FGEN:UW,BBG0077ZBFS3,PRESS STATEMENT: First Gen reports 3Q2015 attributable net income at USD120 million,2015-11-16 04:11:01 +0000,http://www.noodls.com/view/035BC97E307BCF7E5C5D2A58253B68DF89395482,"[at noodls] - November 13, 2015 First Gen Corporation (First Gen) reported net income attributable to equity holders of the parent of USD120 million for the first nine months of 2015. This was a 26%, or a USD43 million, ..."
FGEN,FGEN:UW,BBG0077ZBFS3,FibroGen Announces Third Quarter 2015 Financial Results,2015-11-12 21:16:18 +0000,http://www.noodls.com/view/0B765B6F3B85F03B011AD73A3AA80AFCE03B630E,"[at noodls] - FibroGen Share of US / EU Roxadustat Development Cost Obligations Expected to be Reached in Fourth Quarter SAN FRANCISCO, Nov. 12, 2015 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) ('FibroGen'), a ..."
FGEN,FGEN:UW,BBG0077ZBFS3,"Commit To Purchase FibroGen At $20, Earn 12.4% Annualized Using Options",2015-11-09 16:52:12 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/AhCNEPcmw7s/commit-to-purchase-fibrogen-at-20-earn-124-annualized-using-options-cm540919,"Investors considering a purchase of FibroGen Inc (Symbol FGEN) stock, but tentative about paying the going market price of $25.34 share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in"
FGEN,FGEN:UW,BBG0077ZBFS3,"FibroGen to Report Third Quarter 2015 Financial Results on November 12, 2015",2015-11-05 21:22:23 +0000,http://www.noodls.com/view/EDBD9363620D8E20924C9FDA7E1D3D840D94D4FD,"[at noodls] - FibroGen to Report Third Quarter 2015 Financial Results on November 12, 2015"
FGEN,FGEN:UW,BBG0077ZBFS3,Is FibroGen (FGEN) Stock a Solid Choice Right Now?,2015-09-15 15:23:20 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/uvqtf7f5YoI/is-fibrogen-fgen-stock-a-solid-choice-right-now-cm520086,"One stock that might be an intriguing choice for investors right now is FibroGen, Inc. ( FGEN ). This is because this security in the Medicine Drugs space is seeing solid earnings estimate revision activity, and is in great"
FGEN,FGEN:UW,BBG0077ZBFS3,PRESS STATEMENT: First Gen reports 1H 2015 attributable net income at US.3 million,2015-08-19 09:36:02 +0000,http://www.noodls.com/view/711850FF89BDDD876FA41BD01A3937F113FA2C52,"[at noodls] - August 14, 2015 First Gen Corporation (First Gen) reported net income attributable to equity holders of the parent of US.3 million for the first of 2015. This was a 7.1% or US.3 million decrease from the ..."
FGEN,FGEN:UW,BBG0077ZBFS3,Can Immune Design (IMDZ) Surprise This Earnings Season? - Analyst Blog,2015-08-10 21:02:49 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/D_e2epysHKM/can-immune-design-imdz-surprise-this-earnings-season-analyst-blog-cm507245,"Immune Design Corp.IMDZ is scheduled to report its second quarter 2015 results after the market closes on Aug 12, 2015. Immune Design's track record has not been impressive. The company beat estimates in one of the last three quarters"
FGEN,FGEN:UW,BBG0077ZBFS3,CyberArk Software (CYBR) Q2 Earnings: What's in Store? - Analyst Blog,2015-08-10 20:03:52 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/e9jkR4aPUZg/cyberark-software-cybr-q2-earnings-whats-in-store-analyst-blog-cm507212,"CyberArk Software, Ltd.CYBR is set to report second quarter 2015 results on Aug 11. Last quarter, the company posted a positive earnings surprise of 275%. Let's see how things are shaping up for this announcement.Factors to Consider CyberArk is"
FGEN,FGEN:UW,BBG0077ZBFS3,Why FibroGen (FGEN) Might Surprise This Earnings Season  - Tale of the Tape,2015-08-10 15:05:25 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/gnh9DAasSbM/why-fibrogen-fgen-might-surprise-this-earnings-season-tale-of-the-tape-cm506982,"Investors are always looking for stocks that are poised to beat at earnings season and FibroGen, Inc. ( FGEN ) may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite"
FGEN,FGEN:UW,BBG0077ZBFS3,FibroGen (FGEN) Looks Good: Stock Moves 8.4% Higher - Tale of the Tape,2015-06-22 15:33:16 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/BihIVPKZyoY/fibrogen-fgen-looks-good-stock-moves-84-higher-tale-of-the-tape-cm489206,"FibroGen, Inc. ( FGEN ) was a big mover last session with its shares rising over 8% on the day. The move came on solid volume with far more shares changing hands than in a normal session. This breaks"
FGEN,FGEN:UW,BBG0077ZBFS3,FibroGen (FGEN) Shows Strength: Stock Moves Up 5.7%  - Tale of the Tape,2015-06-04 14:56:17 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/qWjWATpnRY4/fibrogen-fgen-shows-strength-stock-moves-up-57-tale-of-the-tape-cm483443,"FibroGen, Inc. ( FGEN ) was a big mover last session with its shares rising almost 6% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. Yesterday's"
FGEN,FGEN:UW,BBG0077ZBFS3,Aduro Biotech soars 100% on IPO,2015-04-16 14:11:39 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Lehepcn6za4/aduro-biotech-soars-100-on-ipo-cm465740,"Aduro Biotech ( ADRO ) is the latest biotech IPO to soar on its public market debut, as the immunotherapy developer gained over 100% in mid day trading. Aduro boasts impressive backers, a large market opportunity and promising results"
FGEN,FGEN:UW,BBG0077ZBFS3,A Biotech Company With One Of The Normal Risks Reduced,2014-12-09 20:57:31 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/YQ77KQjEnD4/a-biotech-company-with-one-of-the-normal-risks-reduced-cm421428,"Buying stock in young biotech companies is, obviously, inherently risky; most of the time it involves investing in an unproven drug or technology, with an unproven market. As if that wasn’t enough, there is also always the possibility that the company will run out of funds as they wait for that anticipated revenue"
